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DISSERTATION 
  
 
 
 
 
 
 
 
 As a foodborne pathogen, Listeria monocytogenes (Lm) encounters many barriers to 
invasion and dissemination in the host that may change the nature of host response.  Lm has been 
most commonly studied using intravenous (i.v.) inoculation, however, a method that delivers a 
bolus of bacteria directly to the bloodstream.  Thus, little is known about what systemic and local 
mediators are triggered during the natural course of infection and how these may impact 
susceptibility.  Our laboratory used foodborne transmission of Lm in mice to assess whether the 
method of transmission and the specific organ microenvironment could affect infection-induced 
secretion of type I interferon or prostaglandin E2.  Type I interferon is a pro-inflammatory 
effector secreted in response to viruses that has been proposed to paradoxically down-regulate 
innate immunity to intracellular bacteria.  In contrast to i.v. infection, type I interferon was not 
detrimental to the immune response when Lm were acquired orally.  In fact, most of the anti-
inflammatory effects of type I interferon in the spleen were attributable to i.v. but not foodborne 
infection.  Importantly however, downregulation of the receptor for interferon gamma (IFNGR1), 
previously ascribed to the type I interferon response, was found to be a consequence of infection 
and unrelated to type I interferon.  In the liver, robust recruitment and activation of neutrophils 
(PMN) is thought to be required for initiation of Lm immunity.   Prostaglandin E2 (PGE2) is a 
lipid mediator most commonly associated with pain and fever that has also been demonstrated to 
have anti-inflammatory or tolerogenic effects.  It is unknown, however, whether foodborne 
infection induces PGE2 in the liver and if PGE2 then down-regulates PMN activities.  
Recruitment of PMN to the liver following foodborne infection was robust in both susceptible 
and resistant animals.  Bone marrow PMN from each killed Lm ex vivo with similar efficiency, 
thus suggesting that if PMN were dysfunctional during the course of natural infection, they were 
responding to cues in the microenvironment.  Accordingly, significantly more PGE2 was made ex 
vivo by cells from the livers of susceptible animals than from resistant animals.  When PGE2 was 
applied to naïve PMN prior to exposure to Lm, it consistently dampened the killing efficiency of 
these cells, suggesting that this lipid better known for its pro-inflammatory roles might have anti-
inflammatory effects during Lm infection.  Overall, these studies indicate that mediators produced 
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as a result of infection may have very different roles dependent on route of inoculation, timing, 
and the specific organ examined. 
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1. Introduction 
1.1 Epidemiology 
 Listeria monocytogenes (Lm) is a gram-positive facultative anaerobe often found in the 
soil and decaying vegetation (1, 2).  Lm is the causative agent of listeriosis, a rare but very serious 
disease that may afflict humans and grazing mammals.  In addition to Lm, more than ten other 
members of the Listeria genus have been identified, but only Listeria ivanovii is recognized as 
pathogenic. Thirteen serotypes of Lm have been described, with four causing most cases of 
human disease.  The commonly used laboratory strain EGDe is one of these four, serovar 1/2a.  A 
recent study, however, found that the reference strains EGD, EGDe, 10403s, and LO28 may all 
be hypovirulent in comparison to clinical isolates belonging to other clonal complexes (3).  
 It is estimated, using fecal carriage studies, that most people will consume Lm-
contaminated foods between 5 and 9 times a year (4).  Lm is a common contaminant of fresh 
produce, nuts, smoked fish, and dairy, and is annually responsible for many national and 
international recalls of both human and animal food products.  In late 2017-early 2018, a massive 
outbreak occurred in South Africa that as of April 2018 had cause 189 deaths from an astounding 
982 laboratory-confirmed cases (5).  The outbreak was associated with consumption of a food 
product called polony, and whole genome sequencing of bacteria isolated from both the 
production plant and the finished product confirmed genetic relatedness of the isolated bacteria.  
In 2016, Lm accounted for a staggering 81%  (47 million out of 58 million total pounds) of the 
total amount of food recalled by the USDA, thanks in large part to contamination of frozen 
vegetable products produced by one company (6).  Nine people in four states were hospitalized 
and diagnosed with listeriosis linked to the isolates from these products with three deaths, one of 
which was confirmed to be directly caused by listeriosis (7).  Another notable recall occurred in 
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2015, when Blue Bell Creameries voluntarily recalled all of its products and shut down 
production following a multi-state outbreak with three deaths.  All of the diagnoses, 10 in total, 
were made in patients who were already hospitalized for unrelated conditions and six of these 
people were positively determined to have consumed products made from the contaminated ice 
cream (8).  This outbreak underscored the idea that although Lm is commonly consumed, some 
level of immune compromise or genetic predisposition is generally required for invasive disease 
to develop. 
 
1.2 Clinical disease and treatment 
 For the majority who ingest Lm, the only symptoms that materialize will be self-limiting 
gastroenteritis or flu-like symptoms (9).  In the elderly, however, or in patients with comorbidities 
such as HIV, cancer, diabetes mellitus, and those on immunosuppressive therapies, the disease 
may progress to invasive listeriosis, characterized by septicemia, meningitis, and/or encephalitis, 
before diagnosis is made (9).  A recent study found that because a diagnosis of invasive listeriosis 
generally results in admission to intensive care, it is the third most costly foodborne pathogen in 
the US (10).  Fortunately, Lm is susceptible to a wide range of antibiotics, including 
trimethoprim–sulphamethoxazole and β-lactams, and provided that proper treatment is initiated 
early, many who are diagnosed will recover.  Once the bacteria have crossed the blood-brain 
barrier, however, treatment becomes more difficult and outcomes are generally less favorable 
(11). 
 In humans, listeriosis presents most often in immunocompromised or elderly individuals 
as sudden-onset meningitis or septicemia and has an annual mortality rate averaging 25% of all 
diagnosed cases (12, 13).  There are also cases noted in adults with no known pre-disposing 
conditions and otherwise healthy immune systems, suggesting that a genetic component may 
contribute to susceptibility, or that a dose threshold exists, below which most symptoms will be 
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self-limiting in immunocompetent individuals.  The infectious dose needed for listeriosis to 
develop is not well understood overall.  The recent ice cream outbreak, however, provided 
investigators with an opportunity to assess Lm levels in a frozen product, where Lm is fully 
capable of persisting but does not grow.  Testing products manufactured before the outbreak on 
the same production line as the implicated products found an average of 380-2100 CFU per 80-
gram unit of product (14).  This is a startlingly low number; previously the infectious dose for 
healthy individuals was estimated to be 10 to 100 million organisms, and for 
immunocompromised people was estimated at 0.1 to 10 million (15).  The incubation period, or 
the time between ingestion of Lm and illness, is also not well-understood, thanks in large part to 
the wide variety of foods which Lm can be found in.  A recent French study which identified 37 
cases from investigations carried out by the French National Institute for Public Health 
Surveillance found a wide range of incubation periods.  Gastroenteritis was observed in as little as 
24 hours, central nervous system and bacteremia cases in 1-14 days, and pregnancy-associated 
cases presented between 17-67 days after suspected ingestion of contaminated foods (16). 
 Listeriosis is a serious concern during pregnancy, necessitating a long list of foods that 
are “off limits” during pregnancy.  Pregnant women may themselves only develop flu-like 
symptoms; however, spontaneous abortion, pre-term birth, and neonatal infection are all potential 
complications for the pregnancy (9, 11, 13).  Recently, a cohort study encompassing 818 cases 
found that one-quarter of diagnosed pregnant women experienced fetal loss prior to 29 weeks of 
gestation (11).  
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1.3 Virulence characteristics 
Environmental adaptations 
  Lm has evolved characteristics that make it both environmentally hardy and insidious in 
human disease.  A saprophyte, Lm has been found in a variety of soils and tested to survive under 
a wide range of soil conditions (1, 2, 17).  As such, it is commonly found contaminating dairies, 
fresh produce, and silage (fermented ruminant feed).  Lm is able to rapidly transition from its 
environmental state into an infective state, a process that requires multiple changes in gene 
regulation in response to changes in temperature, pH, oxygen saturation, and osmolarity.  Two 
transcription factors- the stress response alternative sigma factor σB, and PrfA, control the 
majority of these adaptations (18, 19). 
 Johannson et al. showed that PrfA was controlled by a 5’ UTR thermosensor, which 
adopted secondary structures at various temperatures to ensuring that the virulence genes 
regulated by PrfA are upregulated at 37°C (20).  However, this thermoregulation is thought to 
produce a low, basal level of PrfA only, as intracellular conditions further upregulate PrfA and 
transcription of the virulence genes that it controls (21).  PrfA regulates genes encoding two 
phospholipases; actA, which encodes the actin-polymerizing protein ActA; hly, which encodes 
the cholesterol-dependent pore-forming toxin listeriolysin O (LLO), and mpl, a metalloprotease.  
Loss of any of these genes significantly attenuates Lm virulence; for example, ∆hly mutants 
cannot escape from the phagosome and thus are completely avirulent (22). 
 The transcription factor σB regulates a number of genes useful in environmental stress 
responses, including a glutamate decarboxylase, involved in acid resistance, and a bile sale 
hydrolase (21).  Additionally σB was shown by Nadon, et al. to regulate transcription of one of 
the prfA promoters in vitro, thus the expression of prfA- mediated virulence genes is at least 
partially dependent on σB (23). 
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Invasion factors 
 Lm appears to use two primary invasion factors, known as internalins (Inl), to gain access 
to cells.  Although there are more than 20 cataloged internalins, InlA and InlB are the two major 
invasion factors (24-27).   InlA is a cell-wall anchored protein that interacts with E-cadherin to 
facilitate uptake into enterocytes and goblet cells (27). Addition of InlA to Listeria innocua, a 
normally non-invasive member of the genus, allowed this bacteria to gain receptor-mediated 
entry into Caco-2 cells, which are similar to human intestinal epithelial cells (24).  E-cadherin, 
however, is a major component of adherens junctions, the side-to-side connections of epithelial 
cells, and is not normally accessible from the intestinal lumen.  Pentecost et al. showed that rather 
than disrupting epithelial barrier integrity in the intestine to access E-cadherin, Lm instead uses 
the self-renewing nature of enterocytes to its advantage (28).  When a cell is normally extruded, 
E-cadherin is transiently exposed to the lumen and becomes accessible to Lm.  Thus, the bacteria 
triggers its own uptake without activating host surveillance mechanisms.  InlA- E-cadherin 
interactions are very species-specific, however, and wild type mice do not express the form of E-
cadherin that InlA naturally binds (29, 30), making oral infection of mice inefficient.  
Experimental methods used to alleviate this difficulty are discussed further under section 1.4, 
“Transmission method.” 
 InlB binds Met, a receptor tyrosine kinase, on a variety of cells including hepatocytes, 
and also activates cell signaling mechanisms not triggered by InlA (24, 31, 32).  In vitro, inlB 
expression was found to be necessary for hepatocyte tropism; however, Gregory et al. showed 
that the inlAB operon was not necessary in vivo for infection of hepatocytes (33).  It remains 
unclear, however, what other routes Lm might use to access hepatocytes. 
 Deletion of inlA was shown not to affect bacteria levels in the spleen and liver following 
oral infection of mice (34, 35).  Lm have also been shown in vitro to translocate across intestinal 
M cells independent of internalin function or secretion of the pore-forming toxin LLO (36).  This 
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suggested that Lm utilize other methods to gain access to the intestinal lamina propria.  Drolia et 
al. recently reported that LAP (Listeria adhesion protein) binding of HSP-60 on intestinal 
epithelial cells triggers NFκB signaling in the cell and rearrangement of cell-to-cell adhesion 
proteins, thus allowing Lm to translocate across the epithelium (37).  In this study, ∆lap Lm 
exhibited a significant defect in dissemination to the spleen and liver, more so than the ∆inlA 
strain.   
Cell-to-cell spread 
  In vitro infections as well as extensive work done using i.v. infection of mice has shown 
much of how Lm escapes from the phagosome and begins cell-to-cell spread.  Key virulence 
factors LLO and PLC function in a complementary manner to facilitate Lm vacuolar escape.   If 
not rapidly killed once internalized, Lm utilizes LLO and PLC to lyse the vacuole membrane and 
escape to the cell cytosol (38-41).  Secreted PLC also induces phagosomal assembly of NADPH 
oxidase, a process which secretion of LLO was also recently shown to prevent (42).  To move 
from one adjacent cell to another, Lm uses ActA to polymerize host cell globular actin into 
filamentous F-actin, forming the “comet tails” commonly seen in micrographs and 
immunofluorescent images of intracellular Lm (43, 44).  Extensive work by several groups 
including Tilney and Portnoy (44) showed that actin was polymerized on one pole of the 
bacterium, thus allowing Lm to move away from the building actin tail.  In confluent or adjoining 
cells, once the tail reaches the cell membrane, Lm protrudes into a neighboring cell and is 
eventually taken into that cell, forming a double-membrane vacuole which is again lysed by LLO 
and PLC (41, 44).  This is a particularly useful trait in tissues such as the hepatic parenchyma, 
where it can infect large areas of hepatocytes without needing to encounter complement or 
phagocytic cells.   
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1.4 Mouse Model 
Differential susceptibility in mice 
 In order to compare characteristics that might affect infection in susceptible and resistant 
individuals, two mouse strains are commonly used: susceptible BALB/cBy/J (BALB) and 
comparatively resistant C57BL/6.  (B6) Using intravenous (i.v.) infection, Cheers et al. found that 
the LD50 for B6 mice was 100-fold greater than that of BALB mice.  When these two strains were 
crossed, approximately half of the offspring became resistant, leading to the idea that there was a 
dominant resistance gene in the B6 mouse (45).  Later, the same group showed that overall 
clearance kinetics in the spleen and liver were slowed in the BALB mouse and that early bacterial 
burdens grew differently in the liver than in the spleen (46).  At 24 hours post infection with 104 
Lm, approximately 10-fold more bacteria were present in the livers of BALB mice than in B6, 
whereas burdens were very similar at this point in the spleen.  This suggested that a differential 
early clearance response had taken place in the liver, and the authors speculated that macrophage 
uptake of Lm in the BALB liver could be deficient (46). 
 Overall, most susceptibility differences between mouse strains have been attributed to 
facets of innate immunity, including differential expression of STAT4 and reduced or delayed 
secretion of TNFα, IL-12, and IFNγ (47-50).  The conventional view is that when infected with 
Lm, BALB mice initially tend to produce a Th2 response, which is useful for extracellular 
pathogens and parasites, while B6 mice respond with secretion of Th1 cytokines including IFNγ.  
Both BALB and B6 mice carry a non-functional allele for NRAMP1, a protein associated with 
natural resistance to intracellular bacteria, and are complement-sufficient (51, 52).  A study 
utilizing F2 progeny of BALB and B6 matings mapped susceptibility loci to chromosomes 5 and 
13, designated Listr1 and Listr2 (53).  Later, expression of CXCL11 was mapped to the Listr1 
loci on chromosome 5. (54) Mice carrying the locus had significantly higher hepatic bacterial 
burdens at 24 hours post infection than the control strain, a difference thought to be due to the 
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presence of fewer CD14+ liver-resident mononuclear phagocytes.  Notably, this locus had no 
effect on bacterial burdens in the spleen.  Another study co-localized the diabetes susceptibility 
allele Idd14 in non-obese diabetic (NOD) mice with Listr2 (55), thus adding NOD mice to the list 
of Lm-susceptible animals.    In general, however, the majority of studies of Lm susceptibility 
have used BALB or B6 mice and their derivatives, as these two display the largest difference in 
susceptibility.  Despite extensive study over the past several decades, though, many important 
components of innate immunity to Lm such as the neutrophil response have not been compared in 
these mice. 
 
Sex-based susceptibility 
 Sex-based susceptibility of mice to Lm has not been as clearly defined as strain 
susceptibility.  In humans, gender is often identified as a risk factor for many diseases including 
those of infectious origin; however, a clear gender preference has not been identified in listeriosis 
cases.  An early study by Cheers et al. found no difference in susceptibility in any of the mice 
tested (45), while a much more recent investigation showed that female mice of any strain were 
significantly more susceptible to Lm infection than males.  This difference was thought to be a 
result of increased serum IL-10 (56).  When foodborne infection was used, BALB females were 
more susceptible than males, but interestingly, no sex-based differences were seen in B6 mice 
(35).  For ease of study and to lessen the chances of fighting amongst cage mates, female mice 
were often used in the studies detailed in the later chapters.  However, male mice were also used 
where available or appropriate, and no significant differences in susceptibility, cell function, or 
cell yield per gram of body weight were noted between sexes in these studies. 
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Transmission method 
 Lm has long been studied as a model intracellular pathogen in mice by using intravenous 
infection, a highly reproducible method that has led to the advancement of knowledge in many 
areas of immunology.  Intraperitoneal infection has also been widely used because of its ease and 
reproducibility.  However, with the exception of maternal-fetal vertical transmission, Lm is 
exclusively acquired in humans by the consumption of contaminated food.  Oral infection of mice 
is most commonly done by intragastric (i.g.) inoculation, a process that is extremely investigator-
dependent, and may even induce rapid blood borne spread by esophageal tearing (57).    
Furthermore, i.g. inoculation is thought to decrease transit time through the stomach and small 
intestine, resulting in a large percentage of the inoculum being shed in the feces.  Lecuit et al. 
observed that a single amino acid in E-cadherin was responsible for the species specificity of InlA 
(30).  Shortly thereafter, this group created a mouse expressing human E-cadherin in enterocytes 
and observed that this single change allowed significantly more bacteria to translocate across the 
intestinal epithelium, creating immune responses and pathologies not seen with the ∆inlA mutant 
(29). More recently, inlA was murinized by point mutation, creating “inlAm” (58).  This allowed 
interaction with mouse E-cadherin and therefore the use of lower and presumably more 
physiologic doses.  However, murinization was also found to increase the receptor repertoire of 
InlAm by allowing binding of N-cadherin and furthermore to create inflammation not previously 
noted (59, 60).  It is unclear though what effect this altered tropism has, as murinized and non-
murinized strains of Lm were recently found to spread beyond the intestine in a similar manner 
(61).   
 In order to study natural dissemination, Bou Ghanem et al. developed a foodborne 
method of Lm transmission that more accurately recapitulates the events of infection than other 
transmission methods (35).  After i.v. infection, approximately 90% of the original inoculum is 
found in the liver only minutes after infection (62-64).  The burden quickly begins to grow, 
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peaking at approximately day 3 before clearance mechanisms overcome the rapid bacterial 
growth.  Cheers et al. showed in 1979 that an i.v. dose of 1.2 x 103 Lm yielded an infection that 
peaked at day 2-3 in the spleens and livers of BALB and B6 mice.  Clearance was observed in the 
spleen by day 6 in both mice, but BALB livers were still significantly infected at day 6 when the 
burden in B6 livers had dropped below the limit of detection (46).  D’Orazio et al. showed later 
that an i.v. infection of BALB mice with 2 x 103 CFU yielded a similar peak day, although 
burdens were approximately 10-fold higher (65).  However, this study showed that burdens were 
not cleared from either organ until approximately day 14.  This is a striking difference from the 
earlier study, one that might potentially be explained by the Lm strain used; however, it is 
unknown what strain was actually used in the 1979 study. 
 Using foodborne transmission and a dose of ~5 x 108- 1 x 109 CFU, a very low number of 
bacteria are sometimes found in the liver at 6 hpi, with burdens below the limit of detection at 24 
hpi, indicating that early innate clearance mechanisms are sufficient to remove low numbers of 
bacteria (D’Orazio, SEF, unpublished data).  This is likely due to direct transit from the intestinal 
tissues to the liver via the portal vein.  The burden does not grow to appreciable numbers until at 
least 48 hpi with a peak typically at 5 dpi ((35), Pitts unpublished observations).  This difference 
is because Lm must cross many barriers to dissemination and either establish a fulminant 
infection in the intestinal tissues followed by spread to the liver or be carried to the liver via 
portal vein circulation (depicted in Fig. 1.1 and discussed further in “Spread beyond the 
intestine”).  Clearance after the peak burden is achieved is relatively rapid in the B6 mouse, 
happening at approximately eight dpi in most tissues.  In the BALB, the comparatively higher 
burdens are cleared more slowly, with most organs still bearing high burdens at eight dpi, 
especially if the infection is done during the mouse’s dark cycle (35).  In order to observe similar 
bacterial burdens in the spleen when comparing i.v. and foodborne infection, it is necessary to 
modulate the dose and timing as was done in Chapter 3.  Here, B6 were either infected i.v. with 
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104 CFU and spleens were harvested at 1 dpi or infected by foodborne transmission with 109 CFU 
and spleens were harvested at 3 dpi.  Although not identical, this produced similar CFU burdens 
in the spleen at harvest because of the different kinetics of each infection. 
 Although foodborne transmission of Lm is much more relevant to study of the natural 
course of infection than other methods, it is not without hurdles, particularly with regard to 
natural variation from mouse-to-mouse.  CFU burdens within a group of mice may vary by 10-
fold or more, for example.  Simple techniques to overcome some of these hurdles, such as fasting 
mice overnight prior to infection and housing mice for the duration of the infection on raised wire 
floors to prevent coprophagy, can overcome these issues however. 
 
1.5 Innate immunity to Lm 
Uptake 
  Lm may be phagocytosed by professional phagocytes such as neutrophils (PMN) and 
macrophages or taken up by activating internalin- dependent mechanisms in non-phagocytic cells 
(32, 66).  Complement opsonization, the decoration of the surface of a pathogen with 
phagocytosis-enhancing proteins, is not necessary for phagocytosis of Lm but was shown to 
greatly improve phagocytosis efficiency of human cells (67).  Some discrepancies between work 
done with mouse and human cells exist, however.  Baker et al. showed that cell wall components 
of Lm activate the complement system via the alternative pathway in mouse serum (68).  
Activation of the complement by the alternative pathway in human serum has also been described 
(69), but another group found no role for the heat labile component of serum in opsonization (70).  
A role for complement and IgM, but not IgG, in opsonization of Lm was also described by 
Bortolussi et al. (67).  Regardless of any potential differences between mouse and man, however, 
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complement appears to play a major role in opsonization of Lm where Lm-specific antibodies are 
not present. 
 
Spread beyond the intestine 
   Orally acquired Lm must first pass through the acidic environment of the stomach, 
thought to kill the majority of bacteria, and then gain access to the intestinal lamina propria (35, 
71) before being transported to the liver via the portal vein or the lymphatics (depicted in Fig. 
1.1).   Melton-Witt et al. used signature-tagged infection of guinea pigs to estimate that only 1 in 
106 ingested bacteria reach the lamina propria (72), therefore, portal vein transport of large 
numbers of intact bacteria simultaneously from the intestine to the liver is likely to be a rare 
event.  Lm not transported through portal circulation must disseminate to the mesenteric lymph 
nodes, avoid killing by phagocytes, and then move into general circulation through the lymphatic 
fluid before accessing the liver and spleen. 
 It is unclear how Lm spread from the intestine to the mesenteric lymph nodes.  Lm is 
considered a primarily intracellular pathogen, yet studies have found significant percentages of 
extracellular bacteria after both i.v. and foodborne infection.  Glomski et al. showed that many 
bacteria in both the spleen and the liver after i.v. infection were sensitive to both gentamicin and 
the presence of neutrophils, indicating that the bacteria were extracellular (73).  The bacteria may 
also replicate extracellularly in the gall bladder, allowing them to re-seed the intestine as bile is 
released with each meal (71).  Jones et al. observed that the majority of the intestinal burden after 
foodborne infection was extracellular and that likewise, most of the bacteria in the lymph nodes 
were not inside a cell (74).  Lm was also found to primarily associate with monocytes in the 
intestine and mesenteric lymph nodes, but the cells were not efficiently infected, casting doubt 
that intracellular transport in monocytes was a primary route of dissemination (75). 
13 
 
 I.v., i.p. (intraperitoneal), and i.g. methods all fail to replicate the natural course of 
infection and therefore, little is actually known about the immune response to ingested Lm.  I.v. 
infection rapidly seeds the liver with up to 90% of the inocula, with the remainder largely 
entering the spleen (62-64).  Studies using i.v. infection have found that bloodborne Lm are 
initially trapped by resident macrophages in the liver and spleen (63, 64, 76).  Kupffer cells (KC), 
the resident macrophages of the liver, trap up to 90% of bloodborne bacteria, with the remainder 
trapped by marginal zone macrophages of the spleen (64).  KC were shown to inactivate the 
majority of the bacteria ingested, while marginal zone macrophages do not do so until they 
encounter IFNγ (64).  Regardless, as a result of encountering sequential bottlenecks, ingested Lm 
are likely to arrive at the liver and spleen asynchronously and in much smaller numbers than after 
i.v. infection and activate innate immunity more slowly.  If i.g. inoculation is employed, or if very 
high doses are used, rapid seeding of the liver may be observed.  This has been speculated to be a 
result of direct bloodstream invasion after esophageal tearing, in the case of i.g. inoculation, or 
due to large numbers of bacteria gaining access to portal circulation if overwhelming doses are 
used (77).   
 
Innate immunity in the spleen 
 The spleen is not required for the initial stages of the immune response to Lm; however, 
splenectomized mice fail to develop adaptive immunity to i.v. Lm and are thus susceptible to 
reinfection (76).   Splenic marginal zone macrophages, which recognize bacteria through several 
receptors, move into the white pulp after ingesting Lm, where they begin to establish foci of 
infection characterized by recruitment of PMN and monocytes (76, 78).  Lm-specific CD4 and 
CD8 T cells can be found in the white pulp after 24 h of infection, indicating rapid antigen 
processing once the phagocytes move into the white pulp (76).  When mice were given a very 
high dose i.v. infection in order to more effectively visualize bacteria, PMN began to accumulate 
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in the marginal zone and red pulp of the spleen within 6 h of infection and continued to infiltrate 
until 2 dpi, extending into the white pulp as the CFU burden grew (76). 
 Large numbers of splenic lymphocytes undergo apoptosis as Lm enters the white pulp, a 
process attributed to induction of type I interferon (discussed in section 1.7 and chapter 3) (79).  
Carrerro et al. showed that SCID mice, which lack lymphocytes, were paradoxically more 
resistant to i.v. Lm, suggesting that the lymphocyte apoptosis induced in the spleen was 
negatively regulating immunity.  This study also found that IL-10 induced after apoptosis was a 
key regulator of anti-Lm immunity (79). 
 As with most intracellular pathogens, interferon gamma (IFNγ) is critical for innate 
immunity to Lm and is secreted by CD8+ T cells and NK T cells following infection in an IL-12 
and IL-18-dependent manner.  In wild-type Lm, the pore-forming toxin LLO allows the bacteria 
to escape the phagosome and move to the cytosol, thus inducing rapid secretion of IL-12 and IL-
18 (80).  CD8+ T cells are recruited to the red pulp after i.v. infection, localizing around large 
numbers of Lm and nascently-infected monocytes and macrophages (81).  In agreement with 
previous work using i.v. Lm, several studies have indicated that the interferon gamma receptor 
(IFNGR1), expressed on most myeloid cells and lymphocytes, is critical for immunity to Lm (82, 
83) primarily because of its role in activating macrophages. 
 
Tolerance and innate immunity in the liver 
 The liver is unique in that it receives both portal vein blood, carrying antigens derived 
from the intestinal contents and microbiota, as well as oxygenated arterial blood.  Its structure is 
highly conducive to filtration and allows extremely large amounts of blood flow; however, 
inflammation in the organ is tightly regulated so as to prevent inappropriate reactions to 
nonpathogenic food-derived antigens (84).  Blood flow slows in the liver due to the narrow, 
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honeycomb-like sinusoids, allowing extensive contact between antigens, as well as circulating T 
cells, with the phagocytes and antigen-presenting cells of the liver (84, 85).   
 Although not tightly bound like other endothelial layers, liver sinusoidal endothelial cells 
(LSEC) physically separate the sinusoidal blood from the hepatocyte plates, forming a fenestrated 
layer, under which is known as the space of Disse.  LSEC, which make up nearly 50% of the non-
parenchymal cells of the liver, play a central role in hepatic tolerance.  These cells express several 
Toll-like receptors, scavenger receptors, MHC I and II, costimulatory molecules CD80 and 86, 
and lymphocyte adhesion molecules (86).   Internalized antigen cross-presented on MHC I 
induces antigen-specific T cell tolerance, of high importance because the liver contains a larger 
concentration of T cells than even lymphoid organs.  Antigens can also be transcytosed and 
released into the space of Disse, exposing hepatocytes to antigen too large to pass through the 
fenestrated endothelium.  Furthermore, T cell recognition of antigen presented on MHC I results 
in a reciprocal signal that induces upregulation of PD-L1 on LSEC.  Thus, CD8 T cells rapidly 
proliferate but do not secrete IFNγ and are tolerized.   
 Kupffer cells (KC), the liver’s resident macrophages, exist in the sinusoidal lumen and 
comprise approximately 35% of the steady-state non-parenchymal cells of the liver (86).  These 
cells secrete IL-10 and prostaglandins, suppressing antigen-specific T cell activation, but are 
required for clearance of even low doses of Lm (85, 86). KC are not a homogenous population of 
cells, and opinions differ on both their lifespan and whether they are bone marrow-monocyte 
derived or are repopulated by hepatic stem cells.  KC express high levels of complement receptor 
CR-1 and capture C3b-coated bacteria under flow conditions, but they do not always internalize 
captured bacteria.  Gregory et al. showed that while critical for immunity to Lm, KC did not 
internalize this bacterium.  Instead, Lm remained bound extracellularly and PMN were recruited 
to the site, killing the bacteria (63). 
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1.6 PMN and their role in hepatic listeriosis 
 The fenestrated endothelium of the liver sinusoids and expression of hyaluronan on 
sinusoidal endothelial cells allows PMN to enter the liver via CD44-hyaluronan interaction, 
which can further be augmented during bacterial inflammation by production of serum-derived 
hyaluronan associated protein (87).  Gregory et al. found a 7-fold increase in liver PMN between 
10 min and 6 hours after i.v. injection of Lm, which corresponded with a 10-fold reduction in 
CFU over the same time-period (63).  This demonstrated that upon acute insult, PMN could be 
recruited rapidly to the liver, overcoming the tolerogenic environmental cues. Senescent PMN 
taken up by KC have also been paradoxically suggested to suppress release of cytokines and 
chemokines by KC (88).   
 Direct killing by PMN plays a primary role in hepatic clearance of Lm.  PMN in the liver 
could either kill bacteria released from apoptotic hepatocytes or may directly lyse infected 
hepatocytes, releasing the bacteria from a protective niche and allowing killing (62, 89, 90).  
Neutrophil extracellular traps (NETs) in the liver have also been demonstrated to enhance 
bacterial capture by KC (86).  Carr et al. also demonstrated that PMN were a major contributor to 
TNFα production in the liver (91).  TNFα was previously shown to directly lyse infected 
hepatocytes (92), and another study correlated hepatocyte lysis with PMN being in close 
proximity (93).   While the growth of Lm itself is also thought to lyse infected hepatocytes (90), 
these results are suggestive that TNFα-mediated lysis of infected hepatocytes is a critical role of 
PMN.   
 
Depletion studies 
  Early work to determine the role of PMN in murine listeriosis relied on antibody-
mediated depletion using a clone (RB6-8C5) that was subsequently shown to bind both PMN and 
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monocytes (94-98).  More recent depletion strategies designed to avoid this issue yielded 
conflicting results about the importance of PMN for clearance from the liver (91, 99).  Carr et al. 
demonstrated that specific depletion of hepatic PMN beginning one day prior to infection yielded 
more pronounced susceptibility in the liver than the spleen (91).  This supported previous studies 
which showed an increase in CFU in the liver, but not the spleen, at one day after i.v. infection of 
RB6-8C5-depleted mice (94).  Shi et al. found that PMN localized around foci of infection in the 
liver, but that their specific depletion, beginning immediately post-infection, did not negatively 
impact survival (99). The major difference in these studies appears to be the timing of PMN 
depletion; removal of PMN after the infection by Shi et al. could plausibly have allowed PMN to 
begin killing Lm before the effects of the antibody became apparent. 
 
PMN recruitment to the infected liver 
 Ly6G+ PMN make up less than 1% of the total steady state non-parenchymal cell 
population of the liver (63, 88); however, PMN rapidly increase following infection and PMN-
rich hepatic abscesses have been observed in both BALB/c and B6 mice after i.v. infection (53, 
99).  PMN develop in the bone marrow and are retained by interaction of CXCR4 with CXCL12 
(SDF-1α) and the integrin VLA-4 with endothelial cell VCAM-1, remaining in the marrow for up 
to two days after full maturation (87, 100, 101).   During inflammation, a variety of chemotactic 
factors including leukotriene B4 (LTB4), C5a, IL-8 (CXCL-8 in mice), CXCL1, and CXCL2, 
may stimulate PMN egress to the blood (100, 102).  Hepatic PMN recruitment after i.v. Lm 
infection is sustained by the IL-23/IL-17 axis (103).  After infection, IL-17A is produced by the 
γδ T cell population of the liver (104) and influences several cytokines and chemokines that 
impact PMN recruitment, including IL-6, G-CSF, and GM-CSF (103, 104).  IL-23 is an IL-12 
family member previously demonstrated to maintain IL-17-producing cells and play a PMN-
dependent protective role in several other infection models (103, 105).  Meeks et al. found that 
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IL-23 was required for protection against i.v. Lm, but that its effects were only apparent after 
several days of infection, indicating that redundant factors played a role in early PMN recruitment 
to the liver (103). 
 Leukotriene B4 (LTB4), a lipid derived from arachidonic acid, is a powerful chemotactic 
signal for PMN (106, 107).  Upon initial PMN encounter with apoptotic cells or bacteria, it is 
secreted by the PMN themselves.  It then serves as a signal relay molecule, creating a PMN 
swarm that is sustained until factors produced within the swarm initiate its dispersal (108, 109).  
Formylated peptide receptors (FPR) also play a local role in PMN recruitment within the infected 
tissue.  Mice lacking FPR were significantly more susceptible to i.v. Lm infection than wild type 
controls when CFU were assessed at 2 dpi (110-112). PMN were still found in the livers of these 
mice, however, again suggesting that redundancy amongst chemotactic factors was important for 
PMN migration into the liver, but that other factors could play very specific, non-overlapping 
roles in recruitment to foci of Lm infection. 
 
Use of human vs. murine PMN 
 Significant differences in mouse and human physiology have historically presented some 
barriers to the experimental use of mouse PMN. Although many of these differences can easily be 
overcome, perception has led to human peripheral blood PMN being used even in studies where 
the question primarily relates to a mouse phenotype, such as susceptibility to bacterial disease.  
As the largest population of cells in human blood, PMN are easily obtained from a peripheral 
blood sample.  In contrast, they only account for about 15% of circulating immune cells in the 
mouse (102, 113).  Mouse bone marrow, however, is an abundant source of morphologically 
mature PMN that release both primary and secondary granules and are suitable for functional 
assays including adoptive transfer (114, 115). Murine PMN do possess some functional 
differences compared to human PMN; they lack defensins and respond poorly to the formylated 
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peptide fMLF, although they do possess a strong affinity for penta- and tetra-formylated peptides 
from Lm and Staphylococcus aureus (110, 112, 116). Murine PMN have also been shown to 
migrate more slowly than human blood PMN in chemotaxis assays (117, 118).  
   
1.7 Type I Interferons 
Receptor and signaling 
  Type I IFNs (IFNα/β) are multifunctional cytokines with both pro- and anti-inflammatory 
roles in immunity. The role of these substances in the progression or control of listeriosis is thus 
complex and most studies have failed to appreciate that the way in which infection is performed 
may complicate the final result.  They were first characterized over sixty years ago as substances 
that could “interfere” in viral infections (119).  Over a dozen IFNα subtypes as well as a single 
IFNβ subtype have been identified, and all of these bind the common type I IFN receptor 
(IFNAR), a heterodimer composed of IFNAR1 and IFNAR2 (120, 121) (Fig. 1.2).  The 
predominant signaling pathway activated by ligation of IFNAR involves activation of tyrosine 
kinases JAK1 and TYK2, which in turn phosphorylate STAT1 and STAT2.  Once 
phosphorylated, STAT1 and STAT2 bind interferon response factor (IRF) 9 and translocate to the 
nucleus, where they bind interferon stimulated response elements in DNA to stimulate 
transcription.  Several other STATs, mitogen activated protein kinases (MAPK) and p38, and 
PI3K are also activated by ligation of IFNAR (120, 121).  IFNAR1 is expressed on all nucleated 
cells and binds IFNβ with a higher affinity than any of the IFNα subtypes, and strong similarities 
in expression have been shown between human and mouse cells (122). 
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Expression and secretion 
 Secretion of type I IFN is induced by ligation of Toll-like receptors (TLR) and cytosolic 
sensors such as DDX41 and stimulator of interferon genes (STING) (123, 124).  Cytosolic 
DDX41 senses production of the bacterial second-messengers cyclic di-AMP and GMP, acting as 
a pattern-recognition receptor.  STING is embedded in the endoplasmic reticulum and can act as 
an adaptor protein for DDX41 but also can directly sense cytosolic dinucleotides as well as DNA 
and RNA.  In Lm, cyclic-di-GMP is secreted through multi-drug resistance pumps (125); strains 
that overexpress MDR-T have been characterized as hyper-inducers of IFNβ (126).  Mice in 
which STING has been knocked out produced significantly less type I IFN in response to Lm 
infection than wild type mice; however, this did not affect susceptibility measured by CFU in the 
spleen (127).   
 During viral infection, type I IFNs are secreted by plasmacytoid dendritic cells (pDC) 
after stimulation of endosomal TLR7 and TLR9 together with the MyD88 adaptor (128).  
Stockinger et al. sorted spleen cells to determine that macrophages produce type I IFN 24h after 
intraperitoneal (i.p.) Lm infection (129).  Another study determined that a subtype of TNF and 
iNOS-producing dendritic cells (Tip-DC) made IFNβ in the spleen after i.v. and i.p. Lm infection 
(130). 
 
Influence on immunity to viral challenge 
 Mice lacking the common type I IFN receptor (IFNAR1-/-) were found to be highly 
susceptible to even low-titer challenge with vesicular stomatitis virus, Semliki Forest virus, and 
vaccinia virus, thus demonstrating that IFNα/β signaling was essential for immunity to acute viral 
infection (131).  Type I IFN can prevent or restrict viral replication through a variety of means, 
such as induction of cyclin-dependent kinase inhibitors, upregulation of apoptosis promoters 
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TRAIL and FAS/FASL, and increasing expression of Mx-1, a GTPase which blocks viral 
transcription through interactions with viral proteins (132, 133).  These cytokines also have 
diverse pro-inflammatory effects on the host, such as stimulation of dendritic cell maturation; 
upregulation of MHC-I, MHC-II and costimulatory molecules CD80 and CD86; and increasing 
secretion of antibodies from B cells (134, 135).  It is somewhat unexpected, therefore, that a 
robust type I IFN response may also promote more severe disease during influenza virus infection 
(136, 137).  
Influence on susceptibility to bacterial challenge 
 The role of type I IFN in the response to bacterial challenge is likely to be considerably 
more complex than what has been observed in viral infections.  Type I IFN signaling improved 
disease resistance in mice infected with extracellular encapsulated bacteria Group B streptococci, 
Streptococcus pneumoniae, and E. coli (138).  In fact, mice deficient for IFNα/β or IFNAR1 were 
hyper-susceptible to these bacteria, thought to be due to a failure of macrophages to produce 
TNFα and IFNγ (138).  This same study also suggested that in the case of these bacteria, IFNα/β 
and IFNγ synergized for bacterial clearance.   
 In contrast, the presence of type I IFNs during infection with intracellular bacterial 
pathogens such as Mycobacterium tuberculosis (139, 140), Francisella tularensis (105), 
Salmonella enterica (141), and Lm (142-145) has been generally shown to be detrimental to the 
host.  Like the initial viral studies, studies using IFNAR1-/- mice suggested that IFNα/β signaling 
modulates multiple facets of innate immunity to bacteria.  Down-regulation of IFNGR1, which 
inhibits macrophage responsiveness to IFNγ, was found to be a major consequence of Lm 
infection (82, 83, 146).  Type I IFN also was shown to cause mass apoptosis of splenic T cells by 
sensitizing the cells to Listeria-induced apoptotic signals (144).  In models of both Francisella 
tularensis and i.v. Lm infection, IFNAR1-/- mice recruited more PMN to the spleen (105, 147).  
Another study using i.v. Lm infection found more robust recruitment to TNFα-producing CD11b+ 
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cells to the spleens of Lm-infected IFNAR1-/- mice (142).   In all of these examples, a lack of type 
I IFN signaling resulted in improved bacterial clearance in comparison to wild type mice. 
 
1.8 Prostaglandin E2 
 Prostaglandin E2 (PGE2) is a lipid derived enzymatically from arachidonic acid present 
in the cell membrane.  It is a member of a family of signaling lipids called eicosanoids which 
encompasses leukotriene B4 (LTB4), thromboxane A4, and prostacyclins. Although well-known 
as a pro-inflammatory mediator, PGE2 and the pathways that cause its induction have also been 
widely studied for their role in aberrant polarization of T cell responses and inhibition of 
macrophage function (148-151). The role of PGE2 in the body seems to depend strongly on the 
tissue, the stimulus causing its induction, and the timing of secretion.  For example, PGE2 plays a 
homeostatic role in maintenance of barrier integrity of the gastric mucosa (152), but is also made 
in response to commensal bacteria and limited PMN activation in response to acute mucosal 
infection with Toxoplasma gondii (153).  PGE2 plays a maintenance role in normal kidney 
function and blood pressure (152), but it has also been shown to drive IL-10 secretion in the liver 
after infection or inflammatory stimulus (154, 155).   Suppression of innate immunity by PGE2 
may outweigh its induction of pro-inflammatory pathways in many situations.  
Production 
 PGE2 secretion can be stimulated by mechanical trauma and inflammatory stimuli 
including bacteria (156).  It is derived from a series of enzymatic reactions (depicted in Fig. 1.3) 
beginning with release of arachidonic acid from the cell membrane by one of three phospholipase 
A2 enzymes, a calcium-dependent cytosolic PLA2 (cPLA2), a secreted pLA2 (sPLA2), and a 
calcium-independent pLA2 (iPLA2).  cPLA2 and sPLA2 are inducible and activated by microbial 
components, including secretion of LLO, which causes an intracellular calcium flux (157).  Once 
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arachidonic acid is liberated, it may be oxidized by the cyclooxygenase enzymes (COX-1 and 
COX-2) or by lipoxygenase.  COX modification produces an intermediate product that is further 
enzymatically modified by prostaglandin E synthase (PGES) to produce PGE2.  Three isoforms 
of PGES exist- microsomal PGES (mPGES) 1 and 2 and cytosolic PGES (cPGES).   A study 
using peritoneal macrophages of BALB/c and B6 mice found that BALB/c macrophages express 
higher levels of mPGES and thus produce more PGE2 when stimulated with LPS (150).  Since 
the discovery of the two isoforms in the 1990s, COX-1 has been considered the “housekeeping” 
COX and COX-2 the inducible isoform.  Some studies have contradicted this convention, 
however, and shown that both isoforms are present at homeostasis and induced by inflammation 
(158).  If free arachidonic acid is metabolized by 5-lipoxygenase, this ultimately results in 
leukotrienes including LTB4, a lipid with chemotactic properties for PMN (106, 107).  Activation 
of the 15-lipoxygenase pathway results in secretion of lipoxin A4 (LXA4), a pro-resolution lipid 
produced during the plateau phase of PMN swarming (109, 159, 160). Using human PMN, Levy 
et al. showed that PGE2 exposure switched lipoxygenase activity from predominately 5-
lipoxygenase, producing LTB4, to 15-lipoxygenase, making LXA4, within 5 hours (160).  This 
study provided strong evidence that PGE2 could induce downregulation of the PMN immune 
response. 
 
Receptors and signaling 
 PGE2 can be produced by most nucleated cells, with the notable exception of B 
lymphocytes, and is secreted to the extracellular environment by multidrug resistance transporter 
4 (156, 161, 162).  It is rapidly removed from circulation, making serum measurements difficult, 
and may also be degraded by a dehydrogenase, forming inactive 15-keto PGE2, or albumin, 
forming 15-keto PGA2 and PGB2 (162-165).  In general, PGE2 acts locally, with autocrine and 
paracrine functions noted in many cell types (156).  PGE2 binds four G-protein coupled receptors 
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expressed on a variety of tissues and cells (EP1-EP4) (Fig. 1.4) (152, 166, 167).  EP2 and EP4 are 
coupled to Gαs in the cytoplasm and stimulate an increase in cyclic adenosine monophosphate 
(cAMP) through activation of adenylate cyclase (168).  EP4 can also stimulate a PI3K-dependent 
ERK1/2 pathway and both EP2 and EP4 have been shown to activate GS3K/β catenin signaling, 
demonstrating potential roles in the pathogenesis of certain cancers (162).  Although EP4 has a 
higher affinity for PGE2 than EP2, stimulation of EP2 stably transfected in HEK cells resulted in 
accumulation of more cAMP, speculated to be a result of faster desensitization of EP4 due to 
receptor internalization (168, 169).  Conversely, EP1 and EP3 stimulation results in a decrease in 
cAMP and an increase in intracellular calcium (170).  Dendritic cells were shown to express all 
four EP receptor subtypes, while mouse peritoneal PMN were found to express EP2 and EP4, but 
not EP1 and EP3 (171).  T and B cells also express PGE2 receptors, with both immune 
stimulatory and inhibitory effects reported depending on cellular context (152, 172).   
 
Pro-inflammatory roles of PGE2 
 PGE2 is involved in the classic symptoms of inflammation- warmth, redness, and fever, 
through its roles in vasodilation and lymphocyte recruitment and induction of IL-6 (173, 174).  It 
is considered a strong pro-inflammatory mediator, and as such has quite a number of drugs 
directed at it.  Non-steroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen broadly target 
all prostaglandin production through suppression of both COX-1 and COX-2, thus leading to 
some of their negative side effects such as gastrointestinal bleeding (152).  COX-2 specific drugs 
such as celecoxib, on the other hand, target the inflammatory induction of only COX-2 and have 
fewer side effects (152).  For the purposes of this document, however, the focus will be on the 
anti-inflammatory effects of PGE2. 
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Anti-inflammatory or immunosuppressive roles of PGE2 
 Numerous studies have examined the effect of PGE2 on both T cell responses and 
phagocyte functions and concluded that it is an immunosuppressive compound with a role in 
Th1/Th2 polarization.  PGE2 was shown to suppress IFNγ and IL-2 from Th1 clones, induce 
FOXP3 expression, and prevent anti-CD3-induced proliferation (148, 175).  Recently, outer 
membrane vesicles released by Helicobacter pylori were shown to induce COX-2 expression and 
robust PGE2 secretion in human peripheral blood monocytes.  In turn, this strongly inhibited T 
cell proliferation without stimulating apoptosis (176).  Hutchison and Myers identified PGE2 in 
splenocyte culture supernatants as a factor that suppressed peritoneal macrophage phagocytosis of 
Lm (177).  Using splenocytes stimulated with S. aureus Cowan 1, Kuroda et al. found that PGE2 
strongly suppressed Th1 activation and IFNγ secretion, but that PGE2 secretion in response to in 
vitro stimulation was not significantly different amongst different mouse strains.  From these 
results, they concluded that BALB/c cells were in fact more sensitive to the effects of PGE2 and 
that this sensitivity played a pivotal role in Th2 polarization in BALB/c mice (149).  Later, the 
same group found that LPS or S. aureus-stimulated BALB/c macrophages produced more PGE2 
than B6 macrophages, and that this PGE2 suppressed Th1 activation in an EP-4 dependent and 
self-regulatory manner (150).  Thus, PGE2 modulates aberrant Th2 activation in BALB/c 
myeloid cells in vitro through both differential production and increased sensitivity compared to 
B6 cells. 
 EP2 and EP4-mediated accumulation of intracellular cAMP is thought to result in some 
of the immunosuppressive effects of PGE2 (151, 152, 171, 178-180).  In Histoplasma 
capsulatum-infected macrophages, ligation of EP2 and EP4 resulted in lower levels of 
phagocytosis, decreased phosphorylation of NFκB, and lower secretion of TNFα (178).  In 
alveolar macrophages, EP2 and EP4 ligation inhibited phagocytosis of Klebsiella pneumoniae in 
a cAMP-dependent manner and inhibited killing through effects on NADPH oxidase (151, 179).  
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In activated dendritic cells, PGE2 or EP4 agonism resulted in lower secretion of pro-
inflammatory chemokines, but also upregulated receptors necessary for migration to lymph nodes 
(152).  Also somewhat contradictory, PGE2 treatment of mouse peritoneal PMN resulted in 
accumulation of cAMP and lower TNFα secretion than control cells but enhanced IL-6 
production when the cells were also treated with LPS (171).  This result was suggested to be 
caused by differential signaling of EP2 and EP4. 
 Monocytes and PMN are rapidly recruited to sites of infection, including the intestinal 
lamina propria, mesenteric lymph nodes, the spleen, and the liver (75, 147).  Although many cells 
secrete PGE2, Grainger et al. recently showed that monocytes recruited to the murine intestinal 
lamina propria produced PGE2, thus modulating PMN function in response to T. gondii (153).  
Application of PGE2 to human PMN was shown to inhibit superoxide production in a cAMP- and 
EP2-dependent manner and inhibited chemotaxis to fMLP independent of cAMP accumulation 
(180).  It is largely unknown, however, how PGE2-dependent decrease in one or more killing 
mechanisms might impact the overall ability of PMN to kill pathogenic bacteria.  
 
1.9 Overall hypothesis 
 The release of cytokines, chemokines, and signaling lipids during natural infection with 
foodborne pathogens is an understudied area of microbiology and immunology.  The use of 
intravenous and intragastric infection, while efficient and reproducible for the most part, has 
hampered the synthesis of knowledge of how a relatively mild infection originating from the 
gastrointestinal tract produces life-threatening disseminated infection in vulnerable populations. 
 In this study, foodborne transmission and in vitro infection were used to assess how two 
mediators not classically thought of as part of bacterial infection, IFNα/β and PGE2, impact early 
immunity to Lm.  I hypothesized that IFNα/β, while clearly capable of modulating immune 
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responses, was induced as a result of the infection method and was specifically a consequence of 
a very large number of bacteria initiating colonization of the spleen simultaneously.  
Additionally, I hypothesized that foodborne infection triggered a condition in the livers of 
susceptible BALB/c mice, namely overproduction of PGE2, which led to modulation of PMN 
clearance of Lm.   As predicted, results showed that foodborne infection elicited little production 
of IFNα/β.  Additionally, mice lacking the common type I IFN receptor were not more resistant to 
foodborne Lm infection, a sharp contrast to the phenotype observed with these mice using i.v. 
infection.  These data suggested that most of the detrimental effects attributed to type I IFN 
during listeriosis may actually be an artifact of the i.v. infection model.  
 Furthermore, results demonstrated that murine PMN efficiently kill serum-opsonized Lm 
using both oxidative and non-oxidative mechanisms.  This led to the conclusion that there were 
no intrinsic differences in the capacity of PMN from susceptible BALB/c and resistant B6 mice to 
kill Lm and suggested that if PMN in the BALB/c liver were deficient, they were responding to 
the hepatic microenvironment.  Accordingly, more PGE2 was found in cells removed from 
infected BALB/c livers.  When exogenous PGE2 was applied to bone marrow PMN, it 
significantly decreased their killing efficiency, thus suggesting that overproduction of PGE2 
under infection conditions could modulate the PMN response to Lm. 
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Figure 1.1  Orally-acquired Lm must pass through sequential anatomical barriers and 
bottlenecks to cause infection. 
Up to 90% of an ingested Lm inoculum is either killed in the stomach or shed in feces within a 
few hours (35, 71). Lm that survive must compete with the gut microbiota to gain access to the 
epithelium (181, 182); it has been estimated that invasion of the mucosal barrier is a rare event, 
with only 1 in 106 bacteria reaching the underlying lamina propria (72). If i.g. inoculation is used, 
or if an overwhelmingly large dose (≥109 CFU) is used with any oral infection method, rapid 
dissemination to the liver, presumably via the portal vein, is observed.  Lm not transported 
through portal circulation must disseminate to the mesenteric lymph nodes (MLN), avoid killing 
by activated phagocytes, and then gain access to the blood circulation.  Given the number of 
barriers faced, it is likely that small numbers of Lm reach the spleen and liver asynchronously.  In 
contrast, Lm that are i.v. injected seed the spleen and liver as a large bolus within 10-15 minutes 
after administration (63, 64, 183). 
This figure was published as part of reference (184) (Pitts, et al. 2018). DOI: 
10.3390/pathogens7010013 
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Figure 1.2  Model of type I interferon signaling 
For type I IFN signaling to occur, IFNα or IFNβ must bind IFNAR1, which then recruits IFNAR2 
to form a heterodimer.  These two extracellular-facing proteins are coupled to Tyk2 and Jak1 in 
the cytoplasm, which phosphorylate Stat1 and Stat2, causing them to dimerize, bind interferon 
response factor (IRF9), and then translocate into the nucleus.  Once in the nucleus, an interferon 
response element (ISRE) is bound on DNA, causing transcription. 
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Figure 1.3  Scheme of eicosanoid production 
Arachidonic acid is released from membrane phospoholipids by activated by phospholipase A2 
(PLA2).  If acted upon by cyclooxygenase enzymes (COX1/2), an intermediate prostaglandin is 
produced that may then be further modified by tissue or cell-specific synthases such as 
microsomal PGE synthase (mPGES).  If arachidonic acid is acted upon by the lipoxygenase 
enzymes (5-LOX and 15-LOX), leukotriene B4 (LTB4) and lipoxin A4 (LXA4) are produced.  
PGE2 exposure in PMN may also trigger a switch from 5-LOX to 15-LOX, inducing secretion of 
pro-resolving LXA4 (160).  Non-steroidal anti-inflammatory drugs (NSAIDS) act on the COX1 
and COX2 enzymes.  The intermediate PGH2 may also be acted on by other specific synthases to 
produce other eicosanoid family members, including prostacyclin, thromboxane (TXA2), and 
prostaglandin D2 (PGD2) 
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Figure 1.4  PGE2 receptors 
PGE2 binds four 7-transmembrane spanning G-protein coupled receptors (EP1-EP4).  EP2 and 
EP4 stimulate adenylate cyclase (AC), causing an accumulation of intracellular cyclic adenosine 
monophosphate (cAMP) and activation of protein kinase A (PKA).  One of the downstream 
consequences of this pathway is transcription of COX-2, stimulating a positive feedback loop 
(168).  Ligation of EP4 can also stimulated PI3 kinase (PI3K), causing downstream transcription 
of PGE synthase, also feeding into the positive feedback loop.  Ligation of EP1 causes 
intracellular calcium flux and activation of protein kinase C (PKC) and can also directly block 
activation of AC, and EP3 ligation also directly blocks AC activation.  ERK, extracellular 
signaling related kinase; EGR1, early growth response factor 1, PLC, phospholipase C; DAG, 
diacylglycerol; IP3, inositoltriphosphate 
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2. Materials and Methods 
Bacteria 
Mouse-adapted (inlAm-expressing) L. monocytogenes (Lm) EGDe derivatives SD2000, SD2001 
(kanamycin-resistant) and SD2710 (constitutive GFP) were used in these studies (61, 75). 
Lm EGDe and an isogenic inlA deletion (ΔinlA) mutant were provided by Cormac Gahan 
(University College Cork, Ireland).  Expression of the modified inlAm surface protein allows the 
bacteria to efficiently bind murine E-cadherin, promoting invasion of the intestinal epithelium 
(58).  Lm SD2000 was created by integrating inlAm into the chromosome of Lm ΔinlA  as 
described by Jones et al. (75).  Kanamycin (50 μg/mL) was added to plates for selection of Lm; 
IPTG (isopropyl-β-D-thiogalactopyranoside; final concentration, 1 mM) was added to induce the 
expression of antibiotic resistance genes carried on pIMC3 derivatives. 
Media 
RP-5- medium was comprised of RPMI 1640 [Life Technologies # 21870], 5% FBS [Gemini], 
2.5 mM L-glutamine, 10 mM HEPES, 0.1 mM β2-mercaptoethanol [Sigma-Aldrich].  RP-10- 
medium was identical to RP-5 except with the addition of 10% FBS.  For bone marrow, RP-10- 
was supplemented with 2 mM EDTA and 25 μg/mL gentamicin [Gibco].  RP10+ contained 
100U/mL penicillin and 0.1 mg/mL streptomycin [Sigma].  Flow cytometry buffer contained 
Ca2+/Mg2+-free HBSS, 25mM HEPES, 5mM EDTA, 1% FBS.  Cells were sorted into a 1:1 
mixture of buffer and sterile FBS with the addition of 25 μg/mL gentamicin. 
Mice 
BALBcBy/J (BALB/c; stock # 001026), C57BL/6J (B6; stock # 000664), and B6.129S-
Cybbtm1Din/J (gp91phox-/-; stock # 002365), and IFNγ-/- (stock #002287) mice were purchased from 
The Jackson Laboratory (Bar Harbor, ME) and housed in a specific pathogen-free facility.  The 
IFNγ-/- mice were crossed with Thy1.1/luciferase-expressing C57BL/6 mice (185) (originally 
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obtained from Dr. Robert Negrin, Stanford University) to obtain homozygous Thy1.1+/+IFNγ-/- 
progeny. IFNAR1-/- mice were obtained from Dr. Jayakrishna Ambati (University of Kentucky).    
Both male and female animals were used in all experiments.  Bone marrow was harvested from 
animals 8-16 weeks old; no significant differences were noted in PMN recovery per gram of 
weight between male and female mice.  Animals used for in vivo infection were 6-12 weeks old at 
time of infection.  Mice were euthanized by cervical dislocation.  Blood was collected from the 
aorta immediately after euthanasia and transferred to a serum separator tube (BD), followed by 
centrifugation for 2 min at 20,000 x g.  Serum was stored at 4°C for use the same day or at -80°C 
for later use.  To pre-treat bacteria with serum, autologous mouse serum was added to Lm (10% 
final concentration) and the mixture was incubated at 37°C for 30 min.  Pre-treatment with serum 
alone in the absence of PMN had no effect on Lm growth (data not shown).  Serum was heat-
inactivated by incubating at 55°C for 30 min.  All procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Kentucky. 
In vivo infection 
For in vivo infection, intestinally passaged Lm were grown to early stationary phase in Brain 
Heart Infusion (BHI) broth (Difco) shaking at 37° C (for i.v. infection) or standing at 30° C (for 
foodborne infection) and then aliquots were prepared and frozen at -80° C until use as described 
previously (186).  An aliquot was thawed on ice and cultured for 1.5 h in BHI broth shaking at 
37° C (i.v.) or standing at 30° C (foodborne).  For i.v. infection, Lm were washed once, 
suspended in sterile PBS, and diluted to the appropriate concentration.  A total volume of 200 μL 
was aseptically injected into the lateral tail vein. Uninfected mice received a 200 μL injection of 
sterile PBS via the lateral tail vein.  For foodborne infection, Lm were washed twice and 
suspended in 5 μL of a salted butter (Kroger) plus sterile PBS mixture (3:2 ratio) and then added 
to a 2-3 mm piece of white bread (Kroger).  Mice were fasted for 16-24 hours prior to ingestion 
of the Lm-contaminated bread and housed on raised wire flooring as described previously (187, 
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188).  Uninfected mice were fasted and fed an uncontaminated piece of bread.  For experiments 
requiring only CFU determination, spleens and livers were harvested aseptically and 
homogenized (Fisher PowerGen 1000, 60% power) in sterile water for 30 seconds.  For all CFU 
determination, dilutions were prepared in sterile water (chapter 3) or PBS (chapters 4 and 5) and 
plated on BHI agar with or without Kanamycin and IPTG.  Colonies were counted after 24 h 
incubation at 37°C. 
In vitro infection 
For in vitro infection of PMN, a glycerol stock of each Lm type was struck out onto BHI agar 
(Difco).  After overnight growth, a freshly streaked colony was inoculated into BHI broth and 
grown shaking at 37˚C overnight (16 h). Lm were washed once with Ca2+/Mg2+-free HBSS and 
then diluted in the same buffer to the appropriate concentration for infection.  For in vitro 
infection followed by COX-2 analysis (Fig. 5.1), cells were exposed to Lm SD2000 (MOI =1).  
25 μg/mL gentamicin was added after 2 hr and incubation was continued overnight.   
Isolation of splenocytes 
Spleens were injected with 100 U of type IV collagenase (Worthington) in a total volume of 1 mL 
of HBSS.  Spleens were minced, additional collagenase was added for a final concentration of 
200 U/mL, and the samples were incubated for 30 min at 37°C in 7% CO2.  The digested tissue 
was pushed through a sterile screen (# 80 mesh), filtered, and red blood cells were lysed using an 
ammonium chloride buffer.  For some experiments in Chapter 3 requiring only a single cell 
suspension, spleens were mechanically dissociated by pushing through mesh screens without 
collagenase treatment using a 3-mL syringe plunger.  For CFU determination, a portion of the 
splenocyte single cell suspension was removed and diluted in sterile water prior to plating on BHI 
agar. 
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Liver non-parenchymal cell preparation 
At indicated time points post-infection, mice were euthanized and livers were perfused via the 
hepatic portal vein with 11 mL of collagenase type IV solution (250 U/mL in HBSS), removing 
blood. The perfused tissue was cut into small pieces, transferred to a 50-mL tube containing 
DNase (10 U/mL; Worthington) and collagenase type IV (100 U/ mL) in 10 mL of RP-5- and 
incubated for 35 min shaking at 37°C.  The digested tissue was gently pushed through a mesh 
screen (no. 80 mesh) to create a single cell suspension.  At this point, one tenth of the volume was 
removed for determination of CFU burdens.  Non-parenchymal cells were enriched by allowing 2 
min settling time followed by centrifugation for 1 min at 50 x g at 4°C.  Supernatant was 
centrifuged at 300 x g at 4°C for 10 min, the pellet was suspended in 30 mL of RPMI 1640, and 
the prior two steps were repeated.  Finally, the pellet was suspended in 1.6 mL cold RPMI 1640 
followed by addition of 2.4 mL cold 40% Histodenz (Sigma) in PBS.  The suspension was 
layered under 2 mL of cold RPMI 1640 in 15 mL polypropylene tubes that had been pre-coated 
with FBS.  Samples were centrifuged for 20 min at 4°C at 1500 x g with no brake.  The interface 
was collected and passed through a filter to remove clumps. 
Type I IFN ELISA 
For detection of type I IFN, lymphocytes were depleted from splenocyte suspensions using APC-
conjugated anti-B220 (RA3-6B2) and anti-TCRβ (H57-597) antibodies (eBioscience) and IMag 
anti-APC magnetic beads (BD Biosciences).   This protocol resulted in greater than 90% 
depletion of both B cells and T cells for all samples.  APC-enriched splenocytes were cultured for 
24 h at 37° C in 7% CO2 at a density of 1.0 x 106 cells/200 μL in 96-well flat bottom plates in 
RP10- containing 12.5 μg/mL gentamicin. Cultured cells were centrifuged at 300 x g for 8 
minutes and the supernatants were harvested and stored at -80° C.  Cytokine concentrations were 
determined using the Verikine Mouse IFNβ ELISA kit (PBL Assay Science, Piscataway, NJ) and 
the Mouse IFNα Platinum ELISA kit (eBioscience). 
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IL-10 ELISA 
For IL-10 detection, spleens were harvested aseptically and placed into 2 mL of ice-cold PBS, 
homogenized for 30 seconds (Fisher PowerGen 1000, 60% power), split into aliquots, and stored 
at -80° C.  An aliquot was thawed on ice and centrifuged at 14,000 x g for 10 min, and the 
supernatant was collected.  ELISA was performed using anti-mouse IL-10 capture antibody 
(JES5-16E3), biotin-conjugated anti-mouse IL-10 detection antibody (JES5-2A5), and mouse IL-
10 standard (eBioscience). 
PGE2 EIA 
Prostaglandin E2 was measured using the Prostaglandin E2 Metabolite (PGEM) EIA kit (Cayman 
Chemical No. 514531) according to manufacturer instructions.  Liver non-parenchymal cells 
were gradient-enriched and cultured overnight at a density of 2.5 x 105 cells per well in a final 
volume of 0.5 mL in 24-well low adherence dishes (Corning).  Cells and supernatant from like 
samples were pooled, and proteins were precipitated using four volumes of ice-cold acetone 
followed by incubation at -20˚C for at least 2 hr.  Samples were dried under nitrogen and 
suspended in the kit buffer according to instructions.  Lipids were extracted using ethyl acetate 
according to the protocol supplied in the PGEM assay kit and samples were suspended in the kit 
assay buffer. 
Bone marrow derived monocytes 
BALB/c mice were euthanized and femurs and tibias were removed and flushed with 10 mL RP-
10+.  Red blood cells were lysed by exposure to an ammonium chloride buffer and remaining 
cells were washed and counted.  Cells were plated at 1 x 106 cells/mL in 16 mL in ultra-low 
attachment plates (Corning No. 3262) and m-CSF was added to each plate at a final concentration 
of 20 ng/mL.  Cells were harvested on day 4 or day 5, washed with RP-10-, and plated in low-
adherence 24 well plates (Corning No. 3473) at 2.5 x 105 cells/mL in 1 mL RP-10-.   
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Flow cytometry 
Cells were stained using fluorescently-conjugated antibodies specific for the following molecules: 
CD64 (X-54-517.1), Ly6C (HK1.4), and Ly6G (1A-8), purchased from Biolegend; F4/80 (BM8), 
CD11c (HL3), CD11b (M1/70), CD19 (D3), B220 (RA3-6B2), CD3 (17A2), and streptavidin, 
purchased from eBioscience.  Biotin-conjugated IFNGR1/CD119 (2E2; Biolegend) was detected 
with PE Cy5-conjugated streptavidin (eBioscience).  Intracellular COX-2 was detected after 
incubation with fixation and permeabilization buffer (BD) according to manufacturer instructions 
using FITC-conjugated anti-COX-2 antibody purchased from Cayman Chemical.  Dendritic cells 
were defined as CD11chiF4/80-/lo, macrophages as CD11c-/lo and F4/80hi or CD64hi; B cells as 
CD3-B220+CD19+ or Ly6G-Ly6C-CD19+, T cells as CD3+CD19- or B220-CD3+TCRβ+; PMN as 
Ly6GhiLy6CintCD11b+ or Ly6GhiLy6C+/-, monocytes as Ly6G-Ly6Chi, and B cells as Ly6G- Ly6C- 
CD19+.  Fluorescence was measured using an LSR II flow cytometer (BD Biosciences) or an iCyt 
Synergy sorter and analysis was performed using FlowJo v.10 (Tree Star).  The sort gating 
strategy incorporated live cell and singlet gates prior to gating on individual markers; sort purities 
for PMN ranged from 92-99%.  Following collection, cells were washed twice with RP-10- prior 
to use. 
Bone marrow harvest for PMN enrichment 
Marrow was flushed from femurs and tibias with RP10- supplemented with EDTA and 25 μg/mL 
gentamicin. Cells (two bones per tube) were passed through a sterile mesh filter into a 15 mL 
polyethylene terephthalate (PET) tubes (Corning) and pelleted by centrifugation at 400 x g.  
Erythrocytes were lysed by exposure to 0.2% NaCl for 20 sec followed by addition of an equal 
volume 1.6% NaCl. 
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Density gradient enrichment of PMN 
Following erythrocyte lysis, PMN were enriched as described previously (115).  Briefly, 3 mL 
Histopaque 1077 was gently layered onto 3 mL Histopaque 1119 in a 15 mL PET tube.  Cells 
were resuspended in cold PBS at 8-12 x 106 cells/mL and overlayered on the Histopaque 
suspension at 8-12 x 106 cells per tube.  Tubes were centrifuged according to author’s instructions 
and the bottom layer of cells was recovered and suspended in RP-10- or flow cytometry buffer. 
In vitro killing assay 
PMN (105/well) were plated in 96-well flat-bottom tissue culture-treated plates in 100 μL in RP-
10 and incubated at 37°C in 7% CO2 for 1 hour to allow a period of recovery.  Lm was added at 
the indicated MOI in a volume of 20-40μL to 3-6 wells per sample group.  In each experiment, a 
group of wells contained bacteria only (no PMN) to assess growth/survival.  The plate was 
centrifuged at 300 x g for 5 min and then incubated at 37˚C in 7% CO2.  At each time point, the 
contents of each well was transferred to an individual microcentrifuge tube and wells were 
vigorously washed 3x with PBS and examined microscopically to ensure that all cells were 
removed.  Serial dilutions of each well were prepared in PBS and plated on BHI agar.  The 
percentage of Lm killed was calculated by dividing the number of CFU from wells with PMN by 
the mean number of CFU from wells without PMN. 
Gentamicin protection assay 
Gradient-enriched PMN were plated and exposed to serum-opsonized Lm as described above. 
Gentamicin was added at a final concentration of 10 μg/ml at 10 minutes post infection (mpi).  At 
indicated time points, the cells were washed once with RP-10-, lysed by addition of sterile water, 
and plated on BHI agar. 
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Chemotaxis assay 
An under-agarose assay was used as described previously by Heit and Kubes (118), with the 
exception of the following modifications.  Ultra-pure agarose (1%; Invitrogen) was dissolved in 
Ca2+/Mg2+-free HBSS and diluted with phenol red-free RPMI 1640 containing a final 
concentration of 2.5% FBS. FBS-coated 60 mm petri dishes were filled with 4.5 ml of the agarose 
mixture.  3 mm holes were cored 1 or 2 mm apart (indicated in figure legend) using a sterilized 
template made from a silicone sheet and a hollow punch tool. Either 1 μM formylated synthetic 
peptide (fMIVTLF plus fMIGWII; Bio-Synthesis, Inc.) or 100 nM leukotriene B4 (Cayman 
Chemical No. 20110) diluted in Ca2+/Mg2+-free HBSS was applied to the center well and allowed 
to diffuse into the agarose for 20 min prior to application of gradient-enriched PMN (1 x 
105/well) to the outer wells.  Dishes were incubated at 37°C in 7% CO2 for 3 h. Images were 
acquired in DIC mode with a Nikon A1R confocal microscope, using a 10x air objective with a 
numerical aperture of 0.45 and the transmitted light detector. Image size was 4096 by 4096 pixels 
with a resolution of 0.31 micrometer/pixel.  Distance traveled was determined using the manual 
measurement tool in the NIS-Elements software program (Nikon). 
Immunofluorescent microscopy 
Sorted PMN were plated in RP-10-, rested for 1 hr, and then Cytochalasin D [Sigma] (20 μM in 
DMSO) was added and cells incubated at 37°C in 7% CO2.  Lm SD2710 was added to the wells 
and the plate was centrifuged for 5 min at 300 x g followed by incubation for 5 min at 37°C in 7% 
CO2.  Difco Listeria O Antiserum Poly [BD Biosciences] and goat anti-rabbit IgG–Texas Red 
(Thermo Fisher)  were used to perform differential “in/out” staining as described previously (75).  
Cells were visualized using a Zeiss Axio Imager.Z1 with a 100x/1.4 NA PlanApo oil immersion 
objective and analyzed with AxioVision software. Slides were blinded and examined by two 
different investigators; average values are reported. 
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Reactive oxygen species 
Gradient-enriched PMN were plated in RP-10-, rested for 1 hr, and then centrifuged at 300 x g 
and suspended in Ca2+/Mg2+-free HBSS.  Dihydrorhodamine 123 (DHR, Cayman Chemical No. 
85100) suspended in DMSO and diluted in HBSS was added to wells (final conc. 2.5 μg/mL) 15 
min prior to addition of either Lm or 20 nM PMA diluted in HBSS (Sigma No. P1585).  Plates 
were centrifuged at 300 x g for 5 min and then incubated at 37°C in 7% CO2. To scavenge 
reactive oxygen intermediates, cells were incubated for 90 min with 50 mM 4-hydroxy Tempo 
dissolved in HBSS [Tempol, Sigma No. 176141].  Lm was added at the indicated MOI and 
further incubated for 30 min. DHR was added during the final 15 min of incubation.  In both 
cases, DHR fluorescence was analyzed by flow cytometry in the FL-1 channel after fixation using 
1% paraformaldehyde. 
Serine protease inhibition 
Cells were treated with diisopropylfluorphosphate (DFP; Sigma No. D0879) suspended in 
isopropanol and diluted in HBSS for 30 min at 37°C in 7% CO2.  DHR was added to the wells 
prior to addition of Lm for ROS detection.  For flow cytometry analysis, cells were washed, 
stained with fluorescently-tagged anti-Ly6G antibody, and fixed in 10% formalin after incubation 
with bacteria. 
In vitro PGE2 and PGE2 receptor antagonist treatment 
Cells were treated with prostaglandin E2 (Cayman Chemical No. 14010) suspended in ethanol 
and diluted in RP1-- for the indicated time periods prior to addition of bacteria and further 
assessment of functionality.  For antagonist experiments, cells were treated with EP-2 antagonist 
PF-04418948 (Cayman Chemical No. 15016) or EP4-antagonist L-161,982 (Cayman Chemical 
No. 10011565) suspended in DMSO and diluted in RP10- at a final concentration of 100 nM 
concurrently with 1 uM PGE2. 
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In vivo PGE2 and indomethacin treatment 
For PGE2 supplementation, female B6 mice were injected i.p. with 40 μG 16,16 dM PGE2 
(Cayman Chemical No. 14750) suspended in DMSO and diluted in sterile HBSS once daily, 
beginning immediately after infection.  Organs were harvested on day 4, homogenized, and plated 
on BHI agar.  For indomethacin challenge experiments, female BALB/c mice were injected i.p. 
twice per day with 2 mg/kg indomethacin (Cayman Chemical No. 70270) suspended in DMSO 
and diluted in sterile HBSS. 
Statistical analysis 
Statistical analysis was performed using Prism for Macintosh Version 6.0f (GraphPad).  
Significance was determined using unpaired T-test unless otherwise noted.  P-values < .05 were 
considered significant and are indicated by * <.05, ** <.01, *** <.001, ****<.0001 
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3. Type I IFN Does Not Promote Susceptibility to Foodborne Listeria monocytogenes 
This chapter modified from a paper originally published as “Type I interferon does not promote 
susceptibility to foodborne Listeria monocytogenes.” Pitts MG, Myers-Morales T, and D’Orazio 
SE. The Journal of Immunology. 2016 Apr 1;196(7):3109-16. doi: 10.4049/jimmunol.1502192. 
Tanya Myers-Morales assisted with completion of many of the experiments shown in this 
manuscript. 
 
Summary 
 Type I IFN (IFNα/β) is thought to enhance growth of the foodborne intracellular 
pathogen Listeria monocytogenes (Lm) by promoting mechanisms that dampen innate immunity 
to infection.  However, the type I IFN response has been studied primarily using methods that 
bypass the stomach and, therefore, fail to replicate the natural course of Lm infection.  In this 
study, we compared i.v. and foodborne transmission of Lm in mice lacking the common type I 
IFN receptor (IFNAR1-/-).  Contrary to what was observed using i.v. infection, IFNAR1-/- and 
wild type mice had similar bacterial burdens in the liver and spleen following foodborne 
infection.  Splenocytes from wild type mice infected intravenously produced significantly more 
IFNβ than those infected by the foodborne route.  Consequently, the immunosuppressive effects 
of type I IFN signaling, which included T cell death, increased IL-10 secretion, and repression of 
PMN recruitment to the spleen, were all observed following i.v., but not foodborne transmission 
of Lm.  Type I IFN was also previously shown to cause a loss of responsiveness to IFNγ through 
down-regulation of the receptor IFNGR1 on macrophages and dendritic cells.   However, we 
detected a decrease in surface expression of IFNGR1 even in the absence of IFNα/β signaling, 
suggesting that in vivo, this infection-induced phenotype is not type I IFN-dependent.  These 
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results highlight the importance of using the natural route of infection for studies of host-
pathogen interactions and suggest that the detrimental effects of IFNα/β signaling on the innate 
immune response to Lm may be an artifact of the i.v. infection model. 
 
Introduction 
 Type I IFNs (IFNα/β) are multifunctional cytokines with diverse roles in anti-viral, anti-
bacterial, and anti-tumor immunity. Over a dozen IFNα subtypes as well as a single 
IFNβ subtype have been identified, and all of these bind the common type I IFN receptor 
(IFNAR), a heterodimer composed of IFNAR1 and IFNAR2 (120, 121).  Ligation of IFNAR, 
which is expressed on a variety of immune cells, triggers Jak-Stat signaling and can affect the 
expression of a diverse array of downstream genes (120).  Secretion of type I IFN is induced by 
ligation of Toll-like receptors and cytosolic sensors such as DDX41 and stimulator of interferon 
genes (STING) (123, 124). 
 Studies using mice with a functionally inactivated type I IFN receptor (IFNAR1-/-) 
demonstrated that IFNα/β signaling was essential for immunity to acute viral challenge.  Despite 
otherwise normal immune responses, these animals were unable to restrict replication of vesicular 
stomatitis virus, Semliki Forest virus, or vaccinia virus after a low-titer challenge (131).  Type I 
IFN can directly limit the intracellular niche for viral replication by inducing expression of 
cyclin-dependent kinase inhibitors, pro-apoptotic TRAIL and FAS/FASL, and the Mx-1 gene 
(132, 133).  These cytokines also stimulate dendritic cell maturation; upregulate expression of 
MHC-I, MHC-II and costimulatory molecules; and promote the production of anti-viral 
antibodies in B cells (134, 135).  Although a robust type I IFN response is crucial for clearance of 
most viruses, it has also been correlated with the development of more severe disease during 
influenza virus infection (136, 137).  
44 
 
 The role of type I IFN in the response to bacterial challenge is complex and appears to 
depend on the nature of the pathogen.  Type I IFN signaling improved disease resistance in mice 
infected with Group B streptococci, Streptococcus pneumoniae, and E. coli (138).  In contrast, 
type I IFNs have been characterized as detrimental to the host during infection with intracellular 
bacterial pathogens such as Mycobacterium tuberculosis (139), Francisella tularensis (105), 
Salmonella enterica (141), and Lm (142-144).  Studies using IFNAR1-/- mice suggest that 
IFNα/β signaling can affect several key areas of innate immunity during infection with these 
bacteria.  During Lm infection, IFNα/β signaling inhibited macrophage responsiveness to IFNγ 
and sensitized T cells to apoptotic signals (83, 144).  Type I IFN also limited neutrophil 
recruitment to the spleen during both Francisella and Lm infection (105).  Another study found a 
higher frequency of TNFα-producing CD11b+ cells in the spleens of Lm-infected IFNAR1-/- mice 
(142).   In each of these cases, mice that lacked type I IFN signaling resulted in infections had 
either reduced bacterial burdens or more rapid bacterial clearance compared to wild type mice. 
 Lm is transmitted to humans through the ingestion of contaminated food, but innate 
immunity to Lm is poorly understood because most studies have used either i.v. or i.p. 
inoculation, methods that result in robust systemic growth of Lm without encountering the harsh 
environment of the gastrointestinal tract.  Some previous studies have used oral gavage to infect 
mice; however, this delivery method can result in more rapid spread of Lm to the blood, spleen, 
and liver with significant variability amongst investigators (57).  All of these methods fail to 
replicate the natural course of infection and therefore, disparate effects on host innate immunity 
may be observed. 
 In this study, we compared foodborne transmission of Lm to i.v. infection to determine if 
type I IFN secretion was detrimental to the host when the bacteria were introduced by the natural 
route.  We hypothesized that i.v. infection would trigger robust, rapid IFNβ secretion because a 
bolus of bacteria reached the spleen within minutes of inoculation. Conversely, during foodborne 
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infection, Lm would asynchronously arrive at the spleen over the course of two to three days.  
Therefore, it was expected that foodborne transmission of Lm would not trigger a robust IFNα/β 
response, and that the corresponding host-detrimental effects would not be observed.   As 
predicted, we found that mice lacking the common type I IFN receptor were not more resistant to 
foodborne Lm infection, and that foodborne infection triggered significantly less production of 
IFNβ than i.v. infection.  The data presented here suggest that most of the detrimental effects 
attributed to type I IFN during Lm infection may actually be an artifact of the i.v. infection model.  
 
3.1 IFNα/β receptor deficiency is not beneficial during foodborne Lm infection 
 After i.v. inoculation of Lm, IFNα/β receptor-deficient (IFNAR1-/-) mice resist high titer 
growth in the spleen and clear the infection more quickly than wild type mice (142, 143). 
Intravenously-injected Lm are quickly filtered from the blood by phagocytes in the spleen and 
liver, producing a rapid-onset infection in these organs (78).  However, i.v.-infected IFNAR1-/- 
and wild type mice do not show a significant difference in Lm burdens until 2 days post-infection 
(dpi), with maximal differences observed at 3 dpi (142).  To find out if type I IFN signaling also 
promoted the growth of Lm after oral transmission, we used a natural feeding model of Lm 
infection.  Groups of IFNAR1-/- and wild type C57BL/6 mice were fed a sublethal dose of Lm or 
infected intravenously, and bacterial loads in the spleen and liver were compared. In agreement 
with previous reports, the livers from IFNAR1-/- mice had more than 1000-fold fewer Lm 
compared to wild type mice three days after i.v. infection (Fig. 3.1).  In the spleen, IFNAR1-
deficient mice had 160-fold less Lm than wild type mice.  In contrast, three days after foodborne 
infection there was no significant difference in bacterial burdens in the liver, and the spleens of 
IFNAR1-/- mice had only 20-fold fewer Lm than wild type mice (Fig. 3.1).  These results are 
similar to a recently published report by Kernbauer et al. who showed that i.g. infection of 
IFNAR1-/- and wild type mice with Lm LO28 resulted in equivalent bacterial burdens in the 
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spleen and liver 3 dpi (189).  Even when foodborne infection was allowed to proceed for up to 5 
days, there remained no significant difference between CFU counts in the liver, and differences in 
the spleen were 5-fold or less.  Notably, foodborne infection did not result in the death of any 
mice during the 5-day observation period.  Thus, while the lack of type I IFN signaling was 
clearly beneficial after i.v. Lm infection, it did not alter the progression of foodborne listeriosis. 
 
3.2 I.V. infection induces more robust IFNβ secretion than foodborne infection 
  In contrast to the rapid nature of i.v. infection, ingested Lm must first survive passage 
through the stomach, invade the intestinal epithelium, and then gain access to the circulation via 
the lymphatics before reaching the spleen.  Depending on the size of the inoculum, this process 
typically requires 24 to 48 hours after ingestion of contaminated food (35). With this in mind, we 
hypothesized that the delayed and presumably asynchronous exit of Lm from the gastrointestinal 
tract would trigger a less robust IFNα/β response than a bolus of organisms that arrived in the 
spleen by i.v. inoculation.  Consequently, a phenotype influenced by type I IFN signaling would 
be more easily observed during i.v. infection than during foodborne infection. 
 To test this idea, splenocytes were harvested from mice 24 hours after i.v. or foodborne 
infection (Fig. 3.2A), and lymphocytes were depleted to increase the concentration of 
macrophages and dendritic cells in the samples.  The cells were cultured overnight without 
further stimulation, allowing for ex vivo accumulation of secreted cytokines, and ELISA was used 
to quantify IFNβ.  As shown in Fig. 3.2C, splenocytes from i.v.-infected mice produced more 
IFNβ than did the splenocytes from mice infected by the foodborne route. However, a 
considerable disparity existed in the bacterial burdens of these two groups at this time point.  The 
i.v. infected mice averaged 106 CFU in the spleen, while the orally challenged mice had less than 
200 CFU per spleen (Fig. 3.2B).   
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 To find out if the bacterial burden or the route of transmission was the primary factor 
influencing IFNβ secretion, we next established an infection model that resulted in colonization 
of the spleen for similar periods of time with comparable bacterial loads.  To accomplish this, the 
i.v. dose was lowered to approximately 103 CFU and spleens were harvested 24 h after injection 
(Fig. 3.2D).  Foodborne infection, however, proceeded for 72 hours to give the bacteria time to 
exit the G.I. tract and arrive in the spleen.  This approach resulted in bacterial burdens of 
approximately 104 CFU in all mice, and in both cases the bacteria had colonized the spleen for 
approximately 24 hours (Fig. 3.2E).  Splenocytes were then harvested and cultured overnight to 
assess IFNβ production.  Despite the similarity in bacterial burdens, splenocytes from i.v.-
infected mice still produced significantly more IFNβ than cells from mice that had ingested Lm 
(Fig. 3.2F).  Because the murine common type I IFN receptor binds thirteen IFNα subtypes in 
addition to a single IFNβ (120, 121), it was possible that IFNα secretion could also be influencing 
the susceptibility of wild type mice to i.v. Lm infection.  To test this, the splenocyte culture 
supernatants were also assayed for IFNα; however, little or none was detected (Fig. 3.2G).  Thus, 
as predicted, i.v. infection resulted in a more robust type I IFN response than foodborne infection, 
even when comparable bacterial burdens were present in the spleen.  Furthermore, these results 
suggested that enhancement of bacterial growth by the mechanisms previously attributed to 
IFNα/β signaling might not occur during foodborne infection due to decreased production of type 
I IFN. 
 
3.3 T cell depletion in the spleen is a consequence of i.v., but not foodborne infection 
 One consequence of i.v. Lm infection that has been linked to type I IFN signaling is the 
extensive loss of splenic lymphocytes that occurs within the first few days after infection.  In wild 
type mice inoculated intravenously with 0.1 LD50 of Lm, large numbers of splenic T cells 
upregulated CD69 and underwent apoptosis, with cell death peaking by 3 dpi (190).  When type I 
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IFN signaling was absent, substantially less T cell depletion was observed in the spleen (144).  
Since oral transmission of Lm did not induce robust IFNβ secretion, we hypothesized that there 
would be little T cell loss in the spleen during foodborne listeriosis.  To examine the extent of T 
cell death, groups of wild type and IFNAR1-/- mice were challenged either i.v. or orally and the 
total number of TCRβ+ cells in the spleen 3 dpi was compared to the cell counts of uninfected 
mice.  In agreement with previous work, i.v. infection induced an IFNAR1-dependent loss of 
more than 50% of the TCRβ+ cells in the spleen (Fig. 3.3A).  Following foodborne infection, 
however, there was no significant T cell depletion in either wild type or IFNAR1-/- mice. 
 The presence of apoptotic cells and cellular debris can trigger the scavenger receptor 
CD36 on macrophages, causing the cells to shift from a pro-inflammatory to a regulatory state 
with concomitant production of IL-10 (191, 192).  Because significant T cell loss was only 
observed during i.v. infection, we predicted that i.v., but not foodborne Lm infection would result 
in increased IL-10 production.  To investigate this, spleens from infected wild type and IFNAR1-/- 
mice were homogenized and the amount of IL-10 present was measured directly ex vivo.  As 
expected, spleens from wild type mice contained significantly more IL-10 than spleens from 
IFNAR1-/- mice three days after i.v. infection (Fig. 3.3B).  In contrast, splenic IL-10 production 
did not increase significantly above the concentrations detected in uninfected mice either three or 
four days after foodborne infection. Together, these results suggested that the IFNβ response 
induced by foodborne infection was not substantial enough to trigger T cell loss and subsequent 
increased IL-10 secretion in the spleen. 
 
3.4 IFNα/β signaling does not affect PMN recruitment following foodborne Lm infection 
 Henry et al. previously showed that IFNAR1-deficient mice recruited significantly higher 
numbers of PMN to the spleen following intranasal Francisella infection compared to wild type 
mice (105).  They proposed that a robust IFNα/β response limited the early influx of PMN by 
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preventing γδ T cell expansion and production of IL-17, thereby reducing the ability of wild type 
mice to eliminate bacteria in the early stages of infection.  Based on this observation, we 
hypothesized that the modest IFNβ response triggered by foodborne Lm infection would not alter 
PMN recruitment to the spleen, while robust secretion of IFNβ following i.v. infection would 
limit this influx.  
 To test this, the total number of PMN (Ly6GhiLy6CintCD11b+) in the spleens of wild type 
and IFNAR1-deficient mice was determined by flow cytometry.  Spleens were harvested 48 h 
after i.v. infection and 72 h after foodborne infection.  As shown in Fig. 3.4A, i.v. infection of 
IFNAR1-deficient mice resulted in a greater PMN influx to the spleen compared with wild type 
mice.  Three days after foodborne infection, however, there was no difference in the number of 
PMN in the spleens of IFNAR1-/- and wild type mice.  Thus, PMN recruitment to the spleen was 
strongly enhanced by the loss of type I IFN signaling during i.v. infection, but not during 
foodborne infection.  These data again suggested that the type I IFN response induced during 
foodborne listeriosiss was not robust enough to alter the innate immune response necessary for 
early clearance of Lm. 
 
3.5 IFNGR1 expression decreases on splenic macrophages and dendritic cells during both 
i.v. and foodborne infection  
 IFNβ was also shown to negatively regulate transcription of the receptor for interferon 
gamma (IFNGR1), thereby limiting the ability of macrophages to respond to the presence of IFNγ 
(82, 83).  This would presumably result in less killing of intracellular bacteria and provide a more 
hospitable replicative niche for the growth of Lm in vivo.  Based on the differential IFNβ 
secretion we detected, we hypothesized that decreased surface IFNGR1 expression would be 
observed shortly after i.v. infection, but not following the ingestion of Lm-contaminated food. 
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To test this, splenocytes were harvested from mice 24 hours after i.v. infection, and the 
mean fluorescence intensity (MFI) of IFNGR1 on the surface of macrophages, dendritic cells, B 
cells, and T cells was determined directly ex vivo (Fig. 3.5A).   Although i.v. infection with 103 
CFU resulted in robust IFNβ secretion (Fig. 3.2B), little to no decrease in IFNGR1 expression 
was observed in any of the four cell types examined (Fig. 3.5B).  However, in agreement with 
previous studies, when we increased the inoculum to 104 CFU, IFNGR1 expression on 
CD11chiF4/80-/lo dendritic cells and F4/80hiCD11c-/lo macrophages decreased to levels that were 
approximately 50% of that found on uninfected cells.  In contrast, B cells showed little to no 
change in IFNGR1 levels during high titer i.v. infection, and T cells showed an increase above 
uninfected levels (Fig. 3.5B).  These results suggested that dose-dependent decreases in IFNGR1 
expression occurred primarily on myeloid-derived antigen-presenting cells and that a bacterial 
burden of at least 105 CFU in the spleen (Fig. 3.5C) was required to observe this effect following 
i.v. challenge. At 24 hours after foodborne infection, little to no decrease in IFNGR1 MFI was 
seen on any of the four cell types tested (Fig. 3.5D).  This observation was not surprising, since 
few mice had detectable bacterial loads in the spleen 24 hpi (Fig. 3.5E).  By 48 hpi, however, 
IFNGR1 MFI had decreased by approximately 50% on dendritic cells and macrophages, despite 
the fact that bacterial burdens in the spleen averaged only 102 CFU at this time point. By 72 hpi, 
the MFI of IFNGR1 on dendritic cells and macrophages had decreased to levels similar to those 
seen during high dose i.v. infection.  However, as shown in Fig. 3.5D, at this time point the mice 
had only ~104 CFU in the spleen, a bacterial burden that did not trigger changes in IFNGR1 MFI 
during i.v. infection (Fig. 3.5C).  Thus, down regulation of IFNGR1 expression during foodborne 
infection was dependent on bacterial load in the spleen, but occurred at a significantly lower 
threshold than during i.v. infection.  
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3.6 Infection-induced decreases in IFNGR1 expression are not dependent on type I IFN 
signaling 
 The changes in IFNGR1 levels observed during foodborne infection in the absence of 
robust IFNβ secretion hinted that surface expression of this receptor might not be strictly 
dependent on the presence of a type I IFN signal.  To directly assess the role of IFNα/β signaling 
in down regulation of IFNGR1, groups of wild type and IFNAR1-/- mice were given a high-titer 
dose of Lm intravenously or fed 109 CFU of Lm and IFNGR1 levels were assessed directly ex 
vivo by flow cytometry.  As shown in Fig. 3.6A, IFNGR1 expression on dendritic cells and 
macrophages decreased by approximately one-half in IFNAR1-/- mice, equivalent to or in some 
cases greater than the change seen on cells from wild type mice.  For both groups of mice, B cell 
IFNGR1 expression underwent little change, while expression of this receptor on T cells 
increased.  Thus, infection-induced down-regulation of IFNGR1 was not dependent on type I 
interferon signaling. 
 A variety of cells rapidly produce IFNγ during Lm infection (81, 193, 194) and the 
cytokine can be detected in the blood within 24 to 48 hours of either i.v (142, 143) or foodborne 
(unpublished observation, Bou Ghanem and D’Orazio) transmission.  Therefore, it was possible 
that ligand binding could trigger internalization of IFNGR1 and contribute to the observed 
decrease in surface expression during the timeframe we tested.  If this was the case, then 
infection-induced decreases in IFNGR1 expression should be greater in wild type mice than in 
IFNγ-deficient mice (IFNγ-/-).  To test this, groups of mice were infected i.v. and IFNGR1 
expression was assessed 24 hours later.  As shown in Fig. 3.6B, dendritic cells and macrophages 
from IFNγ-/- mice showed significantly less down-regulation of IFNGR1 than did cells from wild 
type mice.  Although IFNγ-/- mice are more susceptible to Lm infection over time, there was no 
significant difference in Lm burdens between IFNγ-/- and wild type mice 24 hpi (Fig. 3.6C).  
Thus, the difference in IFNGR1 expression was not the result of a disparity in bacterial loads.   
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These results indicated that multiple mechanisms could contribute to decreased surface 
expression of IFNGR1 during infection, and suggested that this phenotype did not contribute 
significantly to the enhanced growth of Lm in IFNAR1-deficient mice.  
 
3.7 Discussion 
 Intravenous infection of mice results in a highly reproducible model of systemic 
listeriosis; however, this method fails to replicate the natural course of infection, which originates 
in the gastrointestinal tract following the consumption of Lm-contaminated foods.  Previous 
studies using i.v. inoculation have suggested that secretion of type I IFN during the early stages of 
listeriosis may promote growth of Lm (142, 143).  In this study, we demonstrated that foodborne 
infection of mice did not elicit a robust type I IFN response in the spleen.  Accordingly, the host-
detrimental effects caused by IFNα/β signaling were not observed when Lm were transmitted by 
the oral route.  The results presented here highlight the necessity of using physiologically relevant 
infection models to address questions regarding the host immune response to infection. 
 Intravenous inoculation is widely used for studies of immunity to Lm because it produces 
a robust infection in mice, with up to 90% of the initial inoculum seeding the spleen and liver 
within 15 minutes (78).  Lm are thought to be removed from the blood by phagocytes surrounding 
the marginal zone of the spleen.  These cells transport Lm to the periarteriolar lymphoid sheath, 
where increases in bacterial burden can be detected as early as 6 hpi (195).  In contrast to the 
rapid nature of i.v. infection, orally acquired Lm typically require 24-48 hours to exit the 
gastrointestinal tract and begin colonizing the spleen (35, 196, 197). To reach the spleen, Lm must 
survive in the harsh environment of the stomach, invade the intestinal epithelium, disseminate to 
the mesenteric lymph nodes, and then gain access to the circulation.  The specific timing of these 
events is unclear, but because of the bottlenecks involved in this process small numbers of Lm are 
likely to exit the intestine in waves, rather than as a bolus.  It is interesting to note that i.p. 
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inoculation, which also involves an indirect route of spread to the spleen, does trigger IFNα/β-
dependent effects that promote Lm growth (144, 198).  We speculate that dissemination of Lm 
from the peritoneum to the spleen occurs more rapidly than spread from the intestinal lamina 
propria, presumably because there are fewer bottlenecks to overcome. 
   Our results differ from that of Kernbauer et al., who recently concluded that type I IFN 
signaling promotes resistance to oral Lm infection because they found that approximately 30% of 
IFNAR1-/- mice died within 5 days after intragastric (i.g.) inoculation (189) .  There are two key 
differences between our studies. First, Kernbauer et al. used two separate i.g. injections (200 µl of 
bicarbonate, and then 200 µl of bacteria) to orally infect mice.  I.g. infection is a more physically 
traumatic method than natural feeding and may promote a pathway of direct bloodstream 
invasion in a user-dependent manner (57).  However, such physical trauma would be expected to 
result in an infection that mimicked i.v. inoculation, and neither our group, nor O’Connell et al. 
saw increased death of i.v.-infected IFNAR1-/- mice compared to wildtype animals (143).  Thus, 
the more likely explanation for the unique result in the Kernbauer et al. study is that they used Lm 
LO28, a strain that overexpresses the multidrug efflux pumps MdrM and MdrT due to a 
spontaneous deletion in the TetR repressor (126, 199, 200).  This results in increased secretion of 
c-di-AMP, greater IRF3 signaling, and hyper-induction of type I IFN compared to either the 
commonly used laboratory strains EGDe or 10403s or other clinical isolates of Lm.   
 Myeloid-derived cells rapidly initiate IFNβ production after exposure to Lm.  In vitro 
infection of bone marrow-derived macrophages and dendritic cells resulted in a clear induction of 
IFNβ mRNA as early as 4-6 hpi (143, 201), and intracellular cytokine staining of Lm-pulsed 
dendritic cells verified that IFNβ protein was secreted 6 hpi (202).  In this study, we manipulated 
the dose and duration of Lm infection to yield similar bacterial burdens in the spleen after oral 
and i.v. challenge, but found that i.v. inoculation still induced significantly more secretion of 
IFNβ from splenocytes than foodborne infection.  The simplest interpretation of these results is 
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that the impetus for robust IFNβ secretion is a sudden exposure to a large bolus of bacteria, which 
infection by the foodborne route would not provide.  There are very few published reports that 
have measured IFNα levels by ELISA during bacterial infection.  However, the amount of IFNβ 
secreted by splenocytes from i.v.-infected mice in this study was similar to that observed in 
mouse serum after cecal ligation and puncture (203) and from primary mouse lung fibroblasts 
following in vitro Chlamydia trachomatis infection (204).  We were unable to detect increased 
IFNα in the spleen during i.v. or foodborne infection, despite the fact that IFNα subtypes 
outnumber IFNβ by a large ratio (121).  Notably, previous measurements of IFNα concentrations 
in either serum or spleen ranged from 30-50 pg/mL 24 hours after i.v. Lm infection (205, 206).  
This may indicate that IFNα is produced by cell types that we did not include in high numbers in 
our splenocyte cultures.   
 Robust IFNβ secretion following i.v. inoculation of Lm triggered significant T cell loss, 
IL-10 secretion, and a dampening of PMN recruitment in the C57BL/6 mice used in this study.  
These findings are consistent with previous studies that suggested type I IFN was detrimental to 
the host during Lm infection (105, 142-144).  None of these IFNβ-dependent effects were 
observed during foodborne infection.  Surprisingly, down-regulation of IFNGR1, a phenotype 
that was previously linked to the induction of type I IFN (82, 83), occurred during both i.v. and 
foodborne infection. Our findings support those of Rayamajhi et al. (83) who found that IFNGR1 
down-regulation was primarily observed in myeloid-derived cells.  They showed that a soluble 
factor was responsible for suppression of IFNGR1 expression during in vivo Lm infection and 
used in vitro treatment of bone-marrow derived macrophages to demonstrate that IFNβ could 
induce this phenotype.  Our findings, however, indicate that IFNα/β signaling is not absolutely 
required for IFNGR1 down-regulation to occur in vivo and suggest that a variety of other signal 
inputs may influence surface expression of this receptor.  For example, IFNγ is quickly produced 
by a variety of cells in the spleen during Lm infection (81, 193, 194), and rapid endocytosis of 
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IFNGR1 due to ligand binding is likely to occur.  Non-ligand based interactions could also 
promote internalization of IFNGR1, as has been shown to occur on T cells following TCR 
engagement (207).  Prior in vitro work has shown that IFNα/β may act as an antagonist for 
IFNGR1 (208); however, it is unclear whether in vivo infection would induce the concentrations 
necessary to achieve these effects. 
 Type I IFN has traditionally been thought of as an immunostimulatory agent critical for 
inducing an anti-viral response, but it is also commonly used to treat autoimmune diseases such 
as relapsing-remitting multiple sclerosis (209).  Thus, the actions of type I interferons are context-
dependent and may be either pro-inflammatory or anti-inflammatory (210, 211). The timing of 
IFNα/β secretion, and the concentration present in any given tissue, are likely to be primary 
factors in determining the downstream effects of a type I IFN response. Future studies of 
microbial pathogens and the type I IFN response to infection should take into account the impact 
that route of transmission may have on both the induction and the effects of this uniquely 
multifunctional family of cytokines. 
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Figure 3.1  Foodborne Lm infection of IFNAR1-/- and wild type (WT) C57BL/6J mice 
results in similar burdens in the liver and spleen. 
Mice were infected i.v. with 9.0 x 104 CFU or fed 109 CFU of Lm SD2000.  Data from 
multiple experiments was pooled for a total of 8-10 mice per group except for the 5 dpi time 
point, which includes 3-6 mice per group. Mean values +/- SD are shown. 
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Figure 3.2  Robust IFNβ secretion is induced by i.v., but not foodborne Lm infection.   
Splenocytes were harvested from infected C57BL/6J mice and a portion was used to determine 
total CFU burden.  B and T cells were depleted from the remaining splenocytes, and the cells 
were cultured overnight to allow for ex vivo accumulation of secreted IFNα/β.  (A), (D), 
Graphical depictions of infection strategies used are shown.  (A) Mice were inoculated i.v. with 5 
x 104 CFU or fed 109 CFU of Lm SD2000 and spleens were harvested 24 h later.  In panel (D), a 
lower i.v. dose was used (1 x 103 CFU) and spleens were harvested 24 h after i.v. and 72 h after 
foodborne infection. (B), (E), Total CFU burdens per spleen are shown. (C), (F), (G), IFNβ or 
IFNα ELISA data are shown. Representative values from one of three (IFNβ) or two (IFNα) 
separate experiments using 2-3 mice per group are shown. Horizontal lines indicate mean values 
for each group; dashed lines indicate limits of detection.  NI, not infected. 
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Figure 3.3  IFNα/β signaling does not promote T cell loss or IL-10 induction during 
foodborne listeriosis.   
C57BL/6J (WT) and IFNAR1-/- mice were infected i.v. with 5-6 x 104 CFU or fed 109 CFU of 
Lm SD2000.  Splenocytes were harvested at the indicated time points, and the total number of 
T cells per spleen (A) and the concentration of IL-10 present in clarified spleen homogenates 
(B) was determined. Pooled data from multiple experiments are shown.  For panel A, values 
for each mouse are shown and horizontal lines indicate means for each group.  For panel B, 
mean values +/- SD are shown; n=6-7 mice per group except WT NI, where n=4.  NI, not 
infected. 
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Figure 3.4  A lack of type I IFN signaling enhances PMN recruitment to the spleen during 
i.v., but not foodborne infection.   
Mice were infected i.v. with 1 x 104 CFU or fed 109 CFU of Lm SD2000 and splenocytes were 
harvested at either 2 dpi (i.v.) or 3 dpi (food).   A) The total number of PMN per spleen is 
shown.  B) Total Lm burdens per spleen are shown; dashed line indicates limit of detection.  
Data from multiple experiments were pooled; mean values are indicated by grey bars (A) or 
horizontal lines (B). 
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Figure 3.5  Lm infection results in decreased IFNGR1 expression on macrophages and 
dendritic cells. 
Mice were infected i.v. with the indicated doses and splenocytes were harvested 24 hpi (B, C) or 
mice were fed 109 CFU, with splenocytes harvested at the indicated time points (D, E). A 
representative histogram depicting the shift in IFNGR1 expression on dendritic cells 24 h after 
i.v. infection is shown in panel (A).  Mean fluorescence intensity values (MFI) for IFNGR1 were 
normalized to the MFI for uninfected splenocytes, which is represented by the dotted line at 1.0 
(B, D). DC, dendritic cell; MΦ, macrophage.  Significance was determined using one-sample t-
test; asterisks indicate mean values significantly different from a hypothetical mean of 1.0. (C, E) 
Total Lm CFU per spleen was determined at indicated time points; dashed line indicates limit of 
detection. 
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Figure 3.6  Infection-induced decreases in IFNGR1 expression are not type I IFN-
dependent. 
A) IFNAR1-/- and C57BL/6J (WT) mice were i.v. infected with 4.0 x 103 CFU or fed 109 CFU 
Lm SD2000 and spleens were harvested at 24 (i.v.) or 72 (food) hpi.  Mean fluorescence 
intensity values (MFI) for IFNGR1 were normalized to the MFI for uninfected splenocytes, 
which is represented by the dotted line at 1.0.  DC, dendritic cell; MΦ, macrophage.  Mean 
values +/- SD are shown; data was pooled from multiple experiments, n= 4-7 mice per group.  
(B, C) IFNγ-/- and C57BL/6J (WT) mice were i.v. infected with 1 x 104 CFU of Lm.  Spleens 
were harvested 24 hours later and IFNGR1 MFI (B) and total CFU burden (C) was 
determined.   Data from two experiments was pooled; horizontal lines indicate mean values. 
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4. Neutrophils from susceptible and resistant mice efficiently kill opsonized Listeria 
monocytogenes 
This chapter modified from “Neutrophils from susceptible and resistant mice kill Listeria 
monocytogenes similarly in vitro.” Pitts, M.G., Combs, T.A., and D’Orazio, S.E.F. Infection and 
Immunity Apr. 2018: 86 (4). doi: 10.1128/IAI.00085-18  
Travis A. Combs contributed to the design and completion of the work shown in figure 2. 
 
Summary 
 Inbred mouse strains differ in their susceptibility to infection with the facultative 
intracellular bacterium Listeria monocytogenes (Lm), largely due to delayed or deficient innate 
immune responses.  Previous antibody depletion studies suggested that PMN were particularly 
important for clearance in the liver, but the ability of PMN from susceptible and resistant mice to 
directly kill Lm has not been examined.  In this study, we showed that PMN infiltrated the livers 
of BALB/c/By/J (BALB/c) and C57BL/6 (B6) mice in similar numbers and both cell types 
readily migrated towards leukotriene B4 in an in vitro chemotaxis assay.  However, CFU burdens 
in the liver were significantly higher in BALB/c mice, suggesting that PMN in the BALB/c liver 
might not be able to clear Lm as efficiently as B6 PMN. Unprimed PMN harvested from either 
BALB/c or B6 bone marrow killed Lm directly ex vivo, and pretreatment with autologous serum 
significantly enhanced killing efficiency for both.  Lm were internalized within 10 minutes and 
rapidly triggered intracellular production of reactive oxygen species in a dose-dependent manner.  
However, PMN from gp91phox-deficient mice also readily killed Lm, which suggested that non-
oxidative killing mechanisms may be sufficient for bacterial clearance. Together, these results 
indicate that there is not an intrinsic defect in the ability of PMN from susceptible BALB/c mice 
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to kill Lm and further suggest that if PMN function is impaired in BALB/c mice, it is likely due to 
locally produced modulating factors present in the liver during infection.  
 
Introduction 
 Lm are facultative intracellular bacteria that cause foodborne disease in humans. In 
mouse models of listeriosis, orally transmitted Lm establish infection in the gut, and then spread 
systemically to the spleen, liver, and gall bladder (35, 71).  Susceptibility to listeriosis varies 
among inbred mouse strains; for example, bacterial burdens rise to significantly higher levels and 
clearance is delayed in BALB/c mice compared to C57BL/6 (B6) or C57BL/10 mice (35, 46, 
212). This difference has been attributed primarily to facets of innate immunity, including 
differential expression of STAT4 and reduced or delayed secretion of TNFα, IL-12, and IFNγ 
(47-50).   
 One mechanism for innate clearance of Lm is direct killing by neutrophils (PMN).  Early 
work to deplete PMN from mice relied on an antibody (clone RB6-8C5) that was subsequently 
shown to bind both PMN and monocytes (94-98).  More recent depletion strategies designed to 
avoid this issue yielded conflicting results about the importance of PMN for clearance from the 
liver (91, 99). PMN in the liver could either kill bacteria released from apoptotic hepatocytes or 
may directly lyse infected hepatocytes, releasing the bacteria from a protective niche (62, 89, 90). 
Despite PMN recruitment to the liver, CFU burdens in BALB/c mice increased steadily for 
approximately 5 days; in contrast, exponential growth of Lm was restricted in B6 livers and the 
number of CFU began to fall after approximately 3 days (35, 46).  This suggests that BALB/c 
PMN might be less efficient at killing Lm than B6 PMN. 
 PMN make up the majority of immune cells in human blood, but only account for about 
15% of circulating immune cells in the mouse (102, 113).  Since human blood is readily available 
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in larger quantities than murine blood, human PMN are most commonly used for in vitro assays 
that study interactions of PMN with bacteria.     Murine PMN lack defensins and have a low 
affinity for the prototypical formylated peptide fMLF, but they do possess a strong affinity for 
formylated peptides derived from Lm and Staphylococcus aureus (110, 112, 116). Differences in 
relative speed and migration distance have also been noted when using murine and human PMN 
were compared in chemotaxis assays (117).  The difficulty in obtaining large numbers of PMN 
from mice and the potential for functional differences with human cells has resulted in a lack of 
studies using murine PMN.  However, PMN isolated from human peripheral blood cannot be 
used to evaluate how PMN contribute to susceptibility or resistance in mouse models of infection.  
 It has been estimated that mature PMN remain in the bone marrow of mice for up to 2 
days before being released into circulation (101).  Boxio et al. first showed that mouse bone 
marrow is an abundant source of morphologically mature PMN and that these cells release both 
primary and secondary granules upon stimulation (114).  Swamydas et al. further refined the 
enrichment protocol and showed that PMN harvested from bone marrow could be used for 
adoptive transfer (115).  In this study, we used PMN enriched from the bone marrow of naïve or 
infected BALB/c and B6 mice and compared the ability of the cells to kill Lm directly ex vivo.  
We demonstrate that murine neutrophils efficiently kill serum-opsonized Lm using both oxidative 
and non-oxidative mechanisms.  We concluded that there were no intrinsic differences in the 
capacity of PMN from susceptible BALB/c and resistant B6 mice to directly kill Lm. 
 
4.1 Hepatic PMN infiltration after foodborne infection is similar in BALB/c and B6 mice 
 Using the foodborne model of listeriosis in mice, Lm colonize the gut tissue for 24-48 
hours and then spread systemically to the spleen and liver (35, 147).   Differences in host 
susceptibility to infection can readily be observed in the liver, where the number of CFU in 
susceptible BALB/c mice is significantly greater than in the more resistant B6 mice (Fig. 4.1A) 
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(35). PMN-rich hepatic abscesses containing Lm were observed in both BALB/c and B6 mice 24 
hours after intravenous infection (53). To verify that PMN were recruited to the liver parenchyma 
after foodborne infection, livers were harvested after portal vein perfusion to remove blood and 
Ly6Ghi cells were identified by flow cytometry.  At 3 dpi, there was a five to ten-fold increase in 
the number of PMN in the liver, with no significant difference observed between BALB/c and B6 
mice (Fig. 4.1A).  Thus, a lack of PMN infiltration did not explain the greater CFU burden in the 
BALB/c liver.  
 After reaching a tissue such as the liver, PMN must further sense and then migrate 
towards specific chemoattractants, a process that was recently shown to create a “swarm” at 
infectious foci (108). To test whether BALB/c cells had a chemotaxis defect, we analyzed the 
ability of gradient- enriched PMN to migrate towards specific signals using an under-agarose 
assay.  We first tested Lm-derived formylated peptides, which were previously shown by Liu et 
al. to induce chemotaxis from mouse PMN in a Boyden chamber assay (111).  A combination of 
two formylated peptides (1 µM fMIVTLF plus 1µM fMIGWII) did not induce migration in the 
under-agar assay, despite triggering a burst of intracellular ROS when applied to either BALB/c 
or B6 PMN, likely a result of low diffusion through the matrix (data not shown).  However, 
leukotriene B4, a lipid-derived chemotactic signal  produced by PMN (106), did induce migration 
of gradient-enriched murine PMN. The maximum distance traveled in three hours was 
approximately 900 μm for both BALB/c and B6 PMN (Fig. 4.1B). Together, these data indicated 
that recruitment of circulating PMN and chemotaxis towards PMN-derived stimuli was similar in 
both susceptible BALB/c mice and resistant B6 mice. 
4.2 Unprimed bone marrow PMN rapidly kill Lm in the presence of autologous serum  
 Although there was no difference in PMN infiltration, increased bacterial growth in 
BALB/c mice could also be due to an intrinsic defect in the ability of BALB/c PMN to kill Lm. 
To test this, we developed an in vitro killing assay using PMN isolated from the bone marrow of 
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uninfected mice.  PMN were enriched using gradient centrifugation, a method that typically 
yielded a 65-80% pure population of Ly6Ghi PMN (Fig. 4.2A).  The remaining cells were Ly6Chi 
monocytes (1-5%), CD19+ B cells (10-20%), and a small number of CD11b+ CD64- cells (data not 
shown).  The enriched PMN were transferred to a 96-well flat-bottom plate and incubated with 
Lm at low MOI for 90 minutes.  As shown in Fig. 4.2B, there was only a 20% decrease in 
detectable CFU within this time frame using PMN from either mouse strain.   
 Bortolussi et al. previously showed that Lm uptake by human PMN was greatly enhanced 
when serum was present (67). To find out if killing efficiency could be improved by exposure to 
serum proteins, we pre-treated late stationary phase bacteria with 10% autologous mouse serum 
for 30 min. prior to the addition of PMN.  As shown in Fig. 4.2C, serum pre-treatment 
significantly increased the killing rate within one hour for both BALB/c and B6 PMN.  In 
contrast, pre-treatment with heat-inactivated serum did not enhance killing of Lm.  Thus, a heat-
labile component found in naïve serum, most likely complement, contributed significantly to the 
ability of PMN to kill Lm in vitro.  Accordingly, serum pre-treatment was used for all subsequent 
killing assays. 
 In the killing assays described above, the percentage of Lm killed was calculated by 
comparing the number of CFU recovered in the presence of PMN to the number of CFU found in 
assay wells that contained only bacteria.  Incubation of Lm in tissue culture media for one hour 
resulted in an approximate doubling of the bacteria (Fig. 4.2D), a pattern that was consistently 
observed in all assays.  The number of CFU recovered after the addition of gradient-enriched 
PMN was significantly less than the initial inoculum (dashed line), demonstrating that the PMN 
were actively killing bacteria within 1 h rather than simply inhibiting growth.   However, given 
that the PMN out-numbered the bacteria in these assays by up to 10-fold, it was surprising that so 
many viable Lm remained in each well. To find out if a longer incubation time would allow the 
PMN to completely clear the inoculum, the killing assay was extended to four hours.  Lm 
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incubated in tissue culture media alone increased more than 30-fold during this time frame (Fig. 
4.2D). When PMN were added, the number of Lm was five-fold higher than the initial inoculum 
but this number represented an approximate 80% killing rate compared to bacterial growth 
without PMN. Thus, prolonged incubation time did not increase the efficiency of killing, and 
extending the incubation period just allowed any bacteria that evaded contact with PMN to 
replicate exponentially.  
  
4.3 Sorted bone marrow PMN maintain viability and killing capacity after in vitro culture.  
 Although gradient centrifugation provided a substantially enriched PMN population to 
study, it was unknown whether any of the killing observed could be ascribed to the contaminating 
cells, which typically made up 20-35% of the enriched population.  To investigate this, three 
populations of cells were sorted from BALB/c and B6 bone marrow:  Ly6GhiLy6C+ PMN, 
Ly6ChiLy6G- monocytes, and the residual Ly6G-Ly6C- cells (Fig. 4.3A).  Each population was 
plated separately and incubated with Lm for one hour.  As shown in Fig. 4.3B, sorted PMN from 
both BALB/c and B6 mice killed nearly 80% of the bacteria.    Neither monocytes nor the 
residual population of primarily B cells were capable of killing the bacteria directly ex vivo.  
These results indicated that murine bone marrow PMN could be sorted without deleterious effects 
and suggested that the killing observed with gradient-enriched cells was attributable only to the 
PMN. 
 To assess the functional ex vivo lifespan of murine bone marrow PMN, sorted cells were 
cultured overnight and inoculated with Lm the following day.  As shown in Fig. 4.3C, PMN 
remained capable of killing 60 to 70% of the inoculum after 24 hours of in vitro culture.  
However, in contrast to what was observed directly ex vivo, Ly6Chi monocytes also killed 
approximately 60% of bacteria.  Surprisingly, even the other cells, which were comprised mainly 
of CD19+ B cells, killed 30-40% of the Lm (Fig. 4.3C).  Therefore, murine PMN are viable and 
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retain efficient killing ability for at least 24 hours after isolation from the bone marrow.  
However, these data indicate that only highly purified sorted PMN should be used for 
experiments involving cells maintained in culture for more than a few hours.   
 
4.4 Bone marrow PMN rapidly internalize and kill Lm intracellularly.  
 Human PMN are known to phagocytose particulate matter within seconds, followed by 
rapid closure of the phagosome, which then fuses with granules containing an array of 
antibacterial compounds (213).  Extracellular killing mechanisms such as PMN extracellular traps 
have also been described (214). To assess the importance of bacterial internalization for in vitro 
killing of Lm, sorted PMN were pre-treated with cytochalasin D, an inhibitor of actin 
polymerization.  Lm constitutively expressing GFP were added and differential “in/out” staining 
was performed 10 minutes later.  Non-permeabilized cells were stained with Texas Red-
conjugated polyclonal anti-Lm antibodies such that cell-associated extracellular bacteria appeared 
yellow (Fig. 4.4A).  Bacteria that were internalized by the PMN, and thus, not accessible to the 
antibodies, appeared green.  As shown in Fig. 4.4A, approximately 90% of the cell-associated Lm 
were intracellular 10 minutes after incubation with either BALB/c or B6 PMN.  Pre-treatment 
with cytochalasin D decreased the percentage of intracellular bacteria, but did not completely 
block uptake.  Killing assays performed simultaneously also showed a significant reduction in the 
percentage of bacteria killed when cytochalasin D was used (Fig. 4.4B). These results indicated 
that phagocytosis contributes to the ability of mouse bone marrow PMN to efficiently kill serum-
opsonized Lm.   
 To investigate the possibility that Lm might be efficiently internalized by murine PMN 
but not killed within the short time period of these assays, a gentamicin protection assay was 
performed to quantify intracellular bacteria.  Lm was added to gradient-purified PMN, and 
gentamicin was added 10 min later.  As shown in Fig. 4.4C, 10 ug/ml gentamicin was sufficient 
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to kill 100% of the 1 x 105 CFU added to each well in the absence of PMN.  At t=25 min, 50-200 
gentamicin-resistant CFU were detected per well (0.05-0.2% of the initial inoculum).  The 
number of intracellular Lm did not change at 35 or 45 minutes post-infection (Fig. 4.4C). These 
data suggested that a small number of Lm may be able to avoid killing and survive intracellularly.  
However, the negligible number of gentamicin-resistant bacteria were not likely to influence the 
percent killed calculations in the in vitro killing assays.  
 
4.5 Lm induces a respiratory burst in unprimed murine PMN 
 One of the ways PMN can kill bacteria is though targeted release of reactive oxygen 
species (ROS).  To measure the induction of ROS in PMN exposed to Lm, dihydrorhodamine 123 
(DHR) fluorescence was used.  DHR diffuses across the cell membrane and fluoresces when 
oxidized to rhodamine by either peroxynitrite, a product of nitric oxide and superoxide, or 
hypochlorous acid (215).  The short incubation period of the assays described here was not likely 
to activate iNOS (216, 217); therefore, in this system, DHR served primarily as a measure of the 
amount of hypochlorous acid produced by the PMN.    
 Gradient-enriched PMN from BALB/c and B6 mice were incubated in media for one 
hour, and then suspended in buffer prior to the addition of serum-opsonized Lm.  As shown in 
Fig. 4.5A, when the bacteria were added at a low MOI, less than 25% of the PMN produced ROS 
within 30 minutes. When 10-fold more bacteria were added, the number of ROS-positive cells 
increased significantly for both BALB/c and B6 PMN.  Thus, unprimed PMN from both mouse 
strains rapidly responded to the presence of Lm by producing ROS in a dose-responsive manner. 
Although increasing the MOI resulted in a more robust respiratory burst, the killing efficiency 
remained at 60 to 80% (Fig. 5.5B), as was observed previously for assays using lower MOI 
(compare to Fig. 2C, 3B, and 4B). Together, these observations suggested that ROS might not be 
required for efficient killing during the in vitro assay. 
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4.6 Murine PMN use both oxidative and non-oxidative mechanisms to kill Lm 
 To specifically assess the importance of ROS for killing of Lm, PMN from gp91phox-
deficient mice were compared to wild type B6 PMN.  These mice lack a functional allele for the 
large gp91 subunit of NADPH oxidase; thus, the enzyme cannot assemble (218).  As shown 
previously, there was a dose-dependent response for wildtype B6 PMN, with an MOI of 10 
inducing more ROS-positive cells than even PMA treatment (Fig. 6A). PMN from gp91phox-
deficient mice produced no detectable ROS at low MOI or after treatment with PMA, but, 2-5% 
of the cells became rhodamine-positive when Lm was added at an MOI of 10.  A simultaneous 
killing assay done with these cells showed that gp91phox-/- PMN were equally capable of killing 
Lm as cells from the wild type NADPH oxidase-sufficient mice, regardless of the MOI used (Fig. 
4.6A).  Thus, in genetically deficient mice that were unable to produce ROS from birth, non-
oxidative mechanisms were sufficient to kill Lm.  
 As an alternate approach to block ROS activity in both BALB/c and B6 mice, 4-hydroxy 
Tempo (Tempol) was used to scavenge superoxide produced in response to Lm.  Tempol is a 
pleiotropic antioxidant with both superoxide dismutase and catalase-like properties (219, 220).  
Gradient-enriched PMN were pre-treated with Tempol for 90 minutes prior to the addition of Lm, 
and DHR was added to the samples to report generation of ROS.  As shown in Fig. 4.6B, 
approximately 20-30% of either BALB/c or B6 PMN produced high levels of ROS within 30 
min, and pre-treatment with Tempol significantly reduced the percentage of ROShi cells detected. 
Tempol treatment also resulted in a 10-15% reduction in killing by PMN from both mouse strains 
(Fig 4.6B).  These data indicated that in mice genetically capable of producing ROS, scavenging 
oxidative intermediates such that less hypochlorous acid was available reduced killing efficiency 
in PMN.  However, these data were also consistent with the conclusion that oxidative killing 
mechanisms are not required to eliminate Lm.  
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 Since oxidative mechanisms were not required to kill Lm, we hypothesized that inhibition 
of proteases such as elastase, cathepsin G, and proteinase 3 would result in at least partial loss of 
killing capacity.  To test this, gradient-enriched PMN were incubated with 
diisopropylfluorophosphate (DFP), a non-specific serine protease inhibitor.  DFP was previously 
reported to inhibit protease activity without affecting production of ROS (221).  Treatment with 5 
mM DFP resulted in a significant reduction in PMN killing ability (Fig. 4.6C). However, 
treatment with 5 mM DFP also completely inhibited the ROS response in PMN exposed to Lm. 
Lowering the concentration to 0.2 mM DFP eliminated the effect on ROS activity, but this 
concentration did not inhibit bacterial killing (Fig. 4.6C).  Therefore, it was not possible to 
determine whether the loss of killing efficiency was due to a loss of serine protease activity or a 
reduction in ROS availability in wildtype mice.  DFP treatment of PMN from gp91phox-deficient 
mice, however, did result in a significant loss of killing, suggesting that full protease activity is 
important for optimal killing in the absence of ROS (Fig. 4.6D). 
 
4.7 PMN harvested from the bone marrow of infected BALB/c and B6 mice kill Lm with 
similar efficiency 
 Since murine PMN largely stay sequestered in bone marrow until receiving a chemotactic 
signal to egress into the circulation, the cells used in our in vitro assays were likely to be less 
activated than cells that are primed to infiltrate infected tissues.  To assess the ability of activated 
cells to kill Lm, we harvested bone marrow from BALB/c and B6 mice 2 days after foodborne 
infection with Lm. At this time point, there are typically no CFU in the bone marrow; however, 
there are cells producing IFNγ, and monocytes still in the marrow have undergone inflammatory 
changes (75).  Likewise, PMN in the marrow of both BALB/c and B6 mice had uniformly 
upregulated CD11b expression (Fig. 4.7A).  CD11b is a component of complement receptor 3, 
and it was previously shown that CD11b increased on the surface of human PMN after activation 
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(222-224).  However, no significant differences were observed for the ability of CD11bhi PMN to 
kill Lm in vitro compared to cells from uninfected mice (Fig. 4.7A). Thus, unprimed cells from 
the marrow of uninfected mice behaved very similarly to primed cells from the marrow of 
infected mice.  
 To assess the ability of activated cells that had already emigrated from the bone marrow, 
we isolated cells from infected livers. Collagenase-perfused livers were harvested from both 
BALB/c and B6 mice at 3.5 days after infection. Non-parenchymal cells, including PMN were 
gradient-enriched and then kanamycin-resistant Lm were added.  As shown in Fig. 4.7B, these 
cells killed 30-40% of the added Lm.  Together, these results suggest that there are no intrinsic 
differences in the ability of PMN from susceptible BALB/c or resistant B6 mice to clear Lm 
infection.  
 
4.8 Discussion 
 To begin to address the possibility that susceptibility to listeriosis was determined by an 
intrinsic defect in PMN function in mice, we developed an in vitro killing assay using PMN 
enriched from murine bone marrow.   We found that murine PMN killed opsonized Lm efficiently 
even without being primed with agents such as PMA or IFNγ. Furthermore, murine PMN could 
be sorted and kept in culture for at least 24 hours without affecting killing ability.  We showed 
that there was no intrinsic difference in the ability of BALB/c and B6 PMN to kill Lm directly ex 
vivo.  However, it is possible that in vivo, there are substances produced in the BALB/c liver that 
inhibit the function of PMN and thus, contribute to the delayed clearance of Lm. 
 In agreement with previous studies using human PMN (67, 225), we showed that 
opsonization with naïve serum significantly improved the ability of PMN to kill Lm.  In vitro, 
complement may be fixed on the surface of Lm through the classical or alternative pathway (67, 
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68).  In vivo, complement is rapidly activated during inflammation and may also be activated by 
either proteases or acute-phase proteins present during infection (226).  The concentration of 
specific complement components in the liver during Lm infection is unknown, but several studies 
have found increased expression of complement receptors on activated PMN (222-224). In 
humans, specific antibodies may also be involved in enhancing uptake and killing of Lm.  Using a 
rabbit model, Vahidy et al. demonstrated that Lm opsonized with immune serum was internalized 
to a significantly greater extent than bacteria treated with non-immune serum  (227).  
 The ROS burst has long been thought of as a primary means by which PMN clear 
microbes, through oxidative damage to bacterial DNA, peroxidation of membrane lipids, and 
other mechanisms (216). ROS might also increase the K+ concentration in vacuoles, raising the 
pH and releasing proteases from an anionic matrix to allow for optimal protease activity (228).  
Assembly of the multicomponent NADPH oxidase is triggered by the act of phagocytosis, 
resulting in targeted release of ROS (229, 230).  However, in this study, only a high MOI induced 
robust intracellular ROS production in PMN and increased ROS activity did not result in more 
efficient killing of Lm.  PMN from mice genetically unable to make ROS from birth had no defect 
in killing Lm, therefore, non-oxidative killing mechanisms are sufficient.  However, in animals 
capable of triggering an ROS burst, modulation of that response led to reduced bacterial killing.  
The loss of killing capacity observed after Tempol treatment was likely due to a disruption in the 
ratio of available oxygen intermediates.  Since Tempol has catalase-like activity and also acts as a 
superoxide dismutase mimetic (219, 220), it presumably depletes the H2O2 that would normally 
be acted upon by myeloperoxidase to form hypochlorous acid, the oxidizing agent for DHR 123 
(215).   
 It is not surprising that Lm can be resistant to killing by oxidative mechanisms, as the 
bacteria are known to produce both catalase and superoxide dismutase as protection against host-
derived ROS (231). Previously, stationary phase Lm were found to be more vulnerable to killing 
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by human PMN than logarithmic phase bacteria, a result that was attributed to lower catalase 
production (232). Furthermore, superoxide dismutase was found to be phosphorylated and thus, 
less active in stationary phase Lm (233). However, in our study, we found no significant 
difference in the ability of murine PMN to kill either logarithmic phase or stationary phase Lm, 
and both cultures produced similar bubbling reactions in the presence of hydrogen peroxide (Pitts, 
unpublished observation).  The Lm cytolysin LLO was also shown to inhibit the activation of 
NADPH oxidase in macrophages (42); however, the toxin may be rapidly degraded in PMN 
(234).   
 PMN granules contain a variety of proteins and peptides that provide non-oxidative 
means of killing bacteria including cathepsin G, elastase, proteinase 3, lactoferrin, and lysozyme 
(235).  Alford et al. showed that purified cathepsin G alone could kill either S. aureus or Lm 
(236).   Since several of these compounds are serine proteases, (236, 237) we expected to find at 
least a partial loss of killing efficiency after pretreatment with DFP, a serine protease inhibitor, 
but this only occurred in a gp91phox-/- background. DFP was previously used to show that serine 
proteases were important for human PMN to kill Streptococcus pneumoniae (238), but ROS 
activity was not monitored in that study, so we cannot make a direct comparison to our results.  
DFP was also used to inhibit proteolysis of CD43 on human PMN stimulated with opsonized 
zymosan; in that study, the DFP did not inhibit ROS generation (221).  This suggests that the 
nature of the phagocytosed particle may determine whether or not DFP impacts the ROS burst.   
 Circulating PMN are readily obtained from human peripheral blood; however, the cells 
are easily affected by ex vivo isolation and labeling techniques, and are prone to rapid cell death 
(101, 239-241). In contrast, mature PMN harvested from the bone marrow have a longer half-life, 
can be maintained in culture for at least 24 hours (114), and as we showed here, are not affected 
by manipulations such as cell sorting.   A key advantage of using unprimed cells, rather than cells 
that have already egressed from the bone marrow, is the ability to study how specific 
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inflammatory signals alter the functional properties of the PMN. An important challenge for 
future work will be to understand how signals in infected tissues such as the liver may affect the 
function of PMN during infection.   
 
 
Figure 4.1 PMN recruitment to the liver following foodborne infection is similar in B6 and 
BALB/c mice  
PMN recruitment to the liver following foodborne infection is similar in B6 and BALB/c mice.  
(A) Mice were fed 3 x 108 CFU of Lm SD2000.  At 3 dpi, livers were perfused and total CFU 
was determined.  Total Ly6GhiLy6C+ PMN found in the non-parenchymal fraction after tissue 
digestion in uninfected (NI) or infected (3 d) mice was also determined.  Pooled results from 
three independent experiments are shown. (B) Migration of gradient-enriched PMN toward 100 
nM leukotriene B4 was monitored using an under-agarose assay.  Representative results from 
one of three independent experiments are shown (n=4 technical replicates per group).  
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Figure 4.2  Murine PMN kill Lm efficiently in the presence of serum. 
Gradient-enriched PMN were used to perform in vitro killing assays.  (A) Representative dot plot 
shows the composition of a typical gradient enriched bone marrow prep; live and single cell gates 
were applied.  (B) PMN (n=3 technical replicates) were incubated with Lm at a MOI of 0.05 for 
90 min.  Pooled results from 2 independent experiments are shown.  (C) Lm were pre-treated as 
indicated and added to PMN (MOI 0.1) for 60 min.    Representative results from one of three 
independent experiments are shown. (D) Serum-opsonized Lm (MOI=2) was added to BALB/c 
PMN. The absolute number of CFU remaining in the wells at either 1 h or 4 h for a representative 
experiment is shown in the two left graphs. Dashed lines indicate the number of CFU at t=0.  The 
mean percentage killed at each timepoint (+/- SD) for three independent experiments is shown on 
the right.  
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Figure 4.3  Murine PMN rapidly internalize Lm in vitro.  
Sorted murine PMN efficiently kill Lm.  (A) Representative plots depict the three populations of 
cells sorted from marrow of BALB/c (top row) and B6 (bottom row) mice.  (B) Sorted cells were 
plated in media for 1 h and then serum-opsonized Lm was added (MOI=0.1); killing efficiency 
was assessed after 50 min.  (C) Sorted cells were cultured overnight at 37°C in 7% CO2.  The 
following day, a killing assay was performed as described above.  One of two independent 
experiments with 3 technical replicates per group is shown.  
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Figure 4.4  Murine PMN rapidly internalize Lm in vitro. 
(A) Serum-opsonized Lm constitutively expressing GFP (Lm SD2710) was added to sorted PMN 
(MOI=1) that were pre-treated for 45 min with either 20 μM cytochalasin D (cyto D) or DMSO 
(vehicle).  Cell-associated Lm were visualized by differential in/out staining 10 minutes post 
infection. Representative images show intracellular (green) and extracellular (yellow) bacteria 
(scale bar= 2 μM) and the mean percentage of internalized bacteria in three independent 
experiments is shown.  B) A representative killing assay performed at 50 minutes for cells treated 
as in (A); bars indicate mean +/- SD.  C) Gentamicin protection assay performed with serum-
opsonized Lm and gradient-enriched PMN (n=3 technical replicates) and incubated for 10 min 
before addition of gentamicin. Gentamicin was added at t=0 as indicated by the arrowheads.  
Data from two independent experiments (Exp 1, Exp 2) are shown. 
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Figure 4.5  Lm induces a dose-dependent ROS burst in murine PMN.   
Gradient-enriched PMN suspended in HBSS were incubated with dihydrorhodamine 123 prior 
to the addition of Lm at MOI=4 (red), MOI=40 (blue); mock infected cells are shown in grey. 
(A) Representative histograms for cells harvested 30 min after addition of bacteria and total 
ROS+ Ly6GhiLy6C+ PMN are shown.  (B) Gradient-enriched PMN were used for an in vitro 
killing assay (MOI=10).  Killing efficiency was assessed after 50 min.  Representative results 
from one of three experiments using n=3-5 technical replicates per treatment are shown.  Bars 
indicate mean +/- SD. 
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Figure 4.6 ROS is not required for efficient in vitro killing of Lm. 
(A) Gradient-enriched PMN from gp91phox-/- and B6 mice were loaded with DHR prior to addition 
of either serum-opsonized Lm or 20 nM PMA. ROS levels were determined at 30 min and a 
killing assay as performed at 50 min. Pooled data from two independent experiments are shown; 
horizontal bars indicate mean +/- SD (B). Gradient-enriched PMN were incubated with 50 μM 
Tempol or vehicle for 90 min. prior to addition of Lm and the percentage of ROShi neutrophils 
and the killing efficiency for these cells was determined. Data from one of three independent 
experiments is shown; bars indicate mean +/- SD. (C) Gradient-enriched BALB/c PMN were 
incubated with DFP for 30 min. at the indicated concentrations prior to addition of Lm (MOI=10). 
ROS activity was determined 30 min later and % killed was determined 50 min after addition of 
bacteria (n=5). Representative results from one of two independent experiments are shown. Solid 
grey histogram indicates uninfected. (G) Gradient-enriched PMN from gp91phox-/- males were 
treated with DFP at the indicated concentrations for 30 min. prior to addition of Lm (MOI=10) for 
an in vitro killing assay.  Bars indicate mean for n=6 replicates from one of two independent 
experiments 
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Figure 4.7  Neutrophils harvested from the bone marrow of infected BALB and B6 mice kill 
Lm with similar efficiency. 
(A) CD11b surface expression on sorted PMN from uninfected mice (NI) or mice fed 3 x 108 
CFU Lm SD2000 (2 dpi) was determined. Representative flow cytometry histograms are shown.  
PMN were incubated with Lm SD2001 for 50 min and the percentage of kanamycin-resistant 
bacteria killed was determined. Bars indicate mean +/- SD for 6 technical replicates from one of 
three independent experiments.  (B) BALB/c and B6 female mice were fed 1 x 109 CFU L. 
monocytogenes and livers were harvested at 3.5 dpi following collagenase perfusion via the portal 
vein.  The enriched non-parenchymal fraction was plated and exposed to Lm SD2001 at the 
indicated MOI for 50 min and the percentage of kanamycin-resistant bacteria killed was 
determined. Bars indicate mean +/- SD for 6 technical replicates from one of two independent 
experiments.   
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5. Prostaglandin E2 is a negative regulator of the neutrophil response to Listeria 
monocytogenes 
Pitts, MG and D’Orazio, SEF 
 
Summary 
 During acute Listeria monocytogenes (Lm) infection, neutrophils (PMN) rapidly infiltrate 
the liver and begin to remove both free bacteria and infected cells.  In the C57BL/6J (B6) mouse, 
hepatic Lm burdens quickly peak and then begin to decline, but in susceptible BALB/cBy/J 
(BALB) mice the bacterial load continues to increase exponentially despite adequate PMN 
recruitment. We previously showed that bone marrow PMN from both mice killed Lm with 
similar efficiency.  This suggests that the microenvironment in the BALB liver may be 
modulating PMN function.   Prostaglandin E2 (PGE2), an immunomodulatory lipid previously 
shown to suppress Th2 responses and PMN effector functions, was produced in significantly 
higher amounts by the mononuclear leukocyte fraction of cells from infected BALB livers than 
cells from infected B6 livers.  PGE2 significantly inhibited in vitro killing of Lm by both B6 and 
BALB PMN, and this loss of function was rescued by PGE2 receptor antagonism.  We previously 
found that PMN isolated from mice lacking the gp91 subunit of NADPH oxidase efficiently 
killed Lm within 50 minutes.  When these PMN were treated with PGE2, however, no loss in 
killing was observed, suggesting that PGE2 was impacting oxidative killing mechanisms.  Data 
also suggests that the presence of PGE2 negatively affects PMN migration and internalization of 
Lm, thus affecting production of reactive oxygen species and overall killing efficiency.  Thus, an 
excess of PGE2 secretion in the infected BALB liver negatively impacts PMN ability to kill Lm 
by blunting multiple killing mechanisms, allowing the bacteria to replicate exponentially during 
critical early stages of the infection. 
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Introduction 
 Prostaglandin E2 (PGE2) is a signaling lipid derived by enzymatic modification of 
arachidonic acid present in the cell membrane.  Related compounds, called eicosanoids, include 
leukotriene B4 (LTB4), thromboxane A4, and prostacyclins.  PGE2 is probably best known for its 
roles in pain and fever; in fact, it is a classic pro-inflammatory mediator with numerous drugs 
directed at its production.  However, there is a growing body of knowledge related to the role of 
PGE2 in inhibition of innate immune responses, such as aberrant T cell polarization, inhibition of 
macrophage function, induction of IL-10 secretion, and suppression of PMN effector functions 
(148-155). The role of PGE2 in the body seems to depend strongly on the tissue, the stimulus 
causing its induction, and the timing of secretion.  In many situations, suppression of innate 
immunity by PGE2 may outweigh its induction of pro-inflammatory pathways.  
 Introduction of mechanical trauma or inflammatory stimuli such as bacteria can stimulate 
production of PGE2, which begins with release of arachidonic acid from the cell membrane by 
one of three phospholipase A2 enzymes.  Two of these, cPLA2 and sPLA2, are inducible, and 
cPLA2 has been shown to be activated by secretion of the cholesterol-dependent cytolysin LLO 
(157).  Once arachidonic acid is liberated, it may be oxidized by the cyclooxygenase enzymes 
(COX-1 and COX-2), producing an intermediate prostaglandin that is further enzymatically 
modified by prostaglandin E synthase (PGES) to produce PGE2.  Three isoforms of PGES exist- 
microsomal PGES (mPGES) 1 and 2 and cytosolic PGES (cPGES).   A study using peritoneal 
macrophages of BALB/c and B6 mice found that BALB/c macrophages express higher levels of 
mPGES and thus produce more PGE2 when stimulated with LPS (150).  Free arachidonic acid 
can also be metabolized by the lipoxygenase pathway, ultimately resulting in leukotrienes 
including LTB4, a lipid with chemotactic properties for PMN (106, 107).  Activation of 15-
lipoxygenase results in secretion of lipoxin A4 (LXA4), a pro-resolution lipid produced during the 
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plateau phase of PMN swarming (109, 159, 160). Using human PMN, Levy et al. showed that 
PGE2 exposure switched lipoxygenase activity from predominately 5-LO, producing LTB4, to 
15-LO, making LXA4 within 5 hours (160).  This study provided strong evidence that PGE2 
could induce downregulation of the PMN inflammatory response. 
 PGE2 is rapidly removed from circulation and may also be degraded by a dehydrogenase 
or by albumin (162-165).  It binds four G-protein coupled receptors, designated EP1-EP4, which 
are expressed on a variety of tissues and cells (152, 166, 167).  Ligation of EP2 and EP4 
stimulates an increase in cyclic adenosine monophosphate (cAMP) through activation of 
adenylate cyclase (168), and it is ligation of these two receptors that is also thought to result in 
many of the immunosuppressive effects of PGE2 (152, 162).   
 Numerous studies examining the effect of PGE2 on innate immune functions have 
concluded that, given the necessary stimulation and environment, it is an immunosuppressive 
compound (152, 156, 162).  More than thirty years ago, Hutchison and Myers identified PGE2 in 
splenocyte culture supernatants as a factor that suppressed peritoneal macrophage phagocytosis of 
Lm (177).  Since then, PGE2 has been observed to be produced at higher levels by stimulated 
BALB cells than B6 cells and additionally, BALB mice were found to be more sensitive to its 
effects than were B6 mice (149, 150).  PGE2 is also a potent inhibitor of production of reactive 
oxygen species and secretion of IL-12 and TNFα from monocytes (151, 153, 242), all of which 
could have impacts on the course of Lm infection. 
 Following foodborne infection, PMN are robustly recruited to sites of Lm colonization 
including the liver (75, 147, 243).  PMN are thought to be necessary for removal of Lm from the 
liver, where they may both lyse infected hepatocytes as well as kill free bacteria (62, 89, 90).  We 
previously showed that bone marrow PMN from susceptible BALB and resistant B6 mice killed 
Lm with similar efficiency in vitro, suggesting that any inhibition of PMN function in the liver 
was an effect of the microenvironment (243).  In this study, we show that PGE2 causes a dose-
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dependent decrease in PMN killing efficiency in vitro, and that PGE2 is produced at higher levels 
by immune cells harvested from the livers of Lm-susceptible BALB mice than cells from resistant 
B6 mice.  These data suggest that PGE2 and its family of eicosanoids should be more closely 
examined as immune modulators as more is learned about the course of dissemination and growth 
of Lm following foodborne infection.   
 
5.1 Lm exposure induces upregulation of COX-2 in myeloid cells in vitro  
 COX-1, thought of as a “housekeeping” enzyme, and COX-2, the inducible 
cyclooxygenase enzyme, are the first enzymes that act on arachidonic acid to produce 
prostaglandins once it has been liberated from the cell membrane.  Although reports are 
somewhat contradictory on the levels of COX-2 at basal levels, this enzyme is considered to be 
induced by inflammatory stimulation (158, 162).  To measure Lm-mediated stimulation of PGE2 
production in myeloid cells, bone marrow-derived monocyte cultures were stimulated with live 
Lm SD2000. Three populations of cells were present, Ly6Chi monocytes, Ly6C-CD64+ 
macrophages, and a transitioning CD64hiLy6Clo/med population (Fig. 5.1A).  As shown in Fig. 
5.1B, COX-2 was expressed in all three populations prior to stimulation.  When cells were 
exposed to heat-killed sonicated Lm or infected with live, replicating Lm, both the MFI and the 
COX-2+ percentage of each cell type increased.  However a lower percentage of monocytes 
(GR1+CD64_) was COX-2+ prior to treatment and these cells responded at a lower level to 
stimulation than macrophages or transitioning cells. 
  
5.2 Lm infection induces PGE2 secretion in the livers of BALB/c mice 
 Since monocytes and PMN infiltrate the liver within three days after foodborne infection 
(Fig. 5.2A, (243)), we next decided to assess COX-2 expression levels in cells harvested from the 
86 
 
livers of infected mice.  At three days after infection, a mixed population of cells was harvested 
from the livers of BALB and B6 mice and enriched for hematopoietic cells using gradient 
centrifugation.  These cells were stained for intracellular COX-2 expression as well as surface 
markers for PMN, monocytes, Kupffer cells, and B and T lymphocytes.  As shown in Fig. 5.2B, 
however, intracellular staining for this enzyme did not reveal any conclusive infection-related 
induction of COX-2, and furthermore did not point to any one cell type as the primary producers 
of PGE2 in response to Lm. 
 PGE2 is often a locally-acting compound and has both autocrine and paracrine functions 
(156).   Additionally, it is metabolized very rapidly, making ex vivo measurement in a mixed 
population of cells difficult (163, 164).   In order to measure PGE2 in the liver, a proxy 
measurement, prostaglandin E2 metabolite (PGEM) was used.  PGEM is a stable converted 
metabolite of PGE2 useful for determining PGE2 secretion in situations where PGE2 is secreted 
but also metabolized by neighboring cells.  First, mice were fed Lm and livers were harvested at 3 
dpi and homogenized.  When clarified supernatants from liver homogenates were tested, PGEM 
measurements were low and variable (Fig 5.2C).  Because of this, we next depleted parenchymal 
cells from collagenase-digested livers and cultured the remaining hematopoetic fraction 
overnight, allowing secretion of PGE2 into the supernatant.  A mixed population of non-
parenchymal cells was isolated from the livers of infected animals to assess PGE2 secretion 
following in vivo infection.  As shown in Fig. 5.2A, this population consisted of neutrophils, 
monocytes, and numerous other cells not stained by Ly6G and Ly6C markers.  Cells from 
infected BALB/c livers, which contained an average of 10-15-fold higher CFU burdens than B6 
livers (Fig. 5.2D), secreted significantly more PGE2 in overnight culture than cells from infected 
B6 livers (Fig. 5.2E).  To address concerns that perhaps the high CFU burden in BALB liver 
cultures was driving PGE2 secretion and understand what stimulus initiated secretion, uninfected 
liver cells were exposed to live Lm or heat killed, sonicated Lm.  For comparison, cells from 
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infected mice were further stimulated with heat killed, sonicated Lm.  As shown in Fig. 5.2F, the 
additional stimulation boosted PGE2 secretion from cells obtained from infected livers; however, 
only cells from infected mice were capable of secreting PGE2 under any of the conditions tested.  
Thus, in vivo conditions in the BALB/c liver initiated PGE2 secretion and that secretion could be 
increased by further stimulation.   
 To assess whether the effects of augmented PGE2 signaling or inhibition could be seen 
on a macroscopic level, mice were treated with either indomethacin, a COX-2 inhibitor, or 
exogenous 16,16 DM PGE2, a receptor agonist, after infection.  However, neither of these 
treatments had a clear effect on CFU burdens in the liver or spleen at 3 or 4 dpi (Figure 5.2G and 
H).  Interestingly, BALB/c mice receiving indomethacin treatment appeared more active and less 
ruffled than mice receiving vehicle treatment.  PGE2 treatment seemed to have no gross effect on 
the behavior or appearance of B6 mice, however. 
 
5.3 PGE2 down-regulates PMN killing efficiency through EP2 and EP4 signaling  
 PGE2 was previously shown to modulate many functions of innate immunity, including 
macrophage phagocytosis and PMN ROS burst and TNFα secretion (153, 171, 179).  It followed, 
therefore, that overproduction of PGE2 could play a role in the growth of Lm observed in 
BALB/c livers.  All of the above-mentioned effects are indirect measures of cell function, 
however.  To directly test the effect of PGE2 on the ability of PMN to kill Lm, an in vitro killing 
assay using bone marrow PMN was used as previously described ((243), chapter 4).  Gradient 
enriched bone marrow PMN were plated in tissue culture media and then treated with PGE2 for 
30 or 90 min., as indicated, before addition of Lm.  As shown in Fig. 5.3A, PGE2 treatment 
yielded a dose-dependent reduction in killing efficiency as compared to vehicle treatment.  The 
highest amounts of inhibition were observed at 1μM after 30 min. of treatment or .1-1 μM after 
90 min. of treatment. Wells in which PMN were treated with PGE2 yielded 33-50% more 
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bacteria than vehicle-treated wells.   As shown in Fig. 5.3B, when the average reduction in killing 
with 1 μM PGE2 was pooled across many samples, similar results were observed with both 
BALB and B6 PMN despite variability from assay-to-assay. 
 Two of the four PGE2 receptors, EP2 and EP4, have previously been shown to be 
responsible for most of the immune-inhibitory actions of PGE2 signaling (168, 171, 172, 179, 
180).  Much of this is thought to be a result of intracellular cAMP accumulation; however, little is 
actually known about how cAMP accumulation affects the direct killing ability of phagocytic 
cells.  To assess the contribution of these two receptors to the PGE2-dependent loss of killing, 
PMN from BALB/c and B6 mice were treated with EP2 and EP4 receptor antagonists 
concurrently with PGE2.  As shown in Fig. 5.3C, PGE2 caused a 20-30% loss of killing 
efficiency.  EP2 antagonism partially rescued this loss of killing, with further rescue observed 
using EP4 antagonism.  Although some variation was again present, nearly full rescue was 
observed in many samples.  These results suggested that the inhibition of PMN killing caused by 
PGE2 was dependent on the EP2 and EP4 receptors. 
 
5.4 PGE2 exerts pleiotropic effects on PMN function 
 EP2 and EP4 ligation mediate an increase in cAMP that was previously shown in murine 
PMN to result in decreased secretion of TNFα after LPS stimulation (171).  Other EP2 and EP4-
dependent effects have also been shown in macrophages, including lower phagocytosis efficiency 
and reduced ROS burst (151, 178).  We previously showed that mouse PMN kill Lm through 
redundant oxidative and non-oxidative mechanisms (chapter 4), but how these receptors influence 
the many mechanisms that PMN use to kill, however, is unknown.  Since reductions in killing 
efficiency after PGE2 treatment averaged 20-30%, we reasoned that there were likely to be 
several small testable effects within the parameters of using bone marrow PMN that added up to 
the larger phenotype. 
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 An under-agarose assay was first employed to assess the effect of PGE2 treatment on 
PMN chemotaxis toward a 1000 nM LTB4 gradient.  Enriched bone marrow PMN from BALB/c 
and B6 mice were suspended in media containing 1 μM PGE2, incubated for 5 min., and added to 
the assay gel.  After 2 hours, maximum distance traveled under the agarose was measured.  As 
shown in Fig. 5.4A, untreated cells traveled 19-35% farther than cells treated with PGE2.  
Because deficiencies in chemotaxis could result in lower bacterial internalization, in/out staining 
after PGE2 pre-treatment was next used to assess the efficiency of phagocytosis.  To obtain a 
pure population of PMN to study, cells were sorted using Ly6G and Ly6C markers. GFP-
expressing bacteria were added to PMN that had been pretreated with PGE2, and in/out staining 
was performed at 10 mpi, a point at which it was already known that most cell-associated bacteria 
could be found intracellularly ((243), chapter 4).  At this point, approximately 10-12% fewer cell-
associated bacteria were found to be intracellular when cells were PGE2-treated (Fig 5.4B). 
 Since internalization of bacteria in PMN results in ROS generation, we next used M-
cherry expressing Lm together with dihydrorhodamine (DHR), which is oxidized to rhodamine 
and fluoresces comparably to FITC in the presence of ROS.  Treatment of cells with 1μM PGE2 
prior to addition of bacteria caused a 5-7% reduction in the percentage of cells detected to contain 
M-cherry bacteria and a comparable reduction in ROS positivity at the same time point (Fig. 
5.4C).  Importantly, however, further assays to detect reductions in ROS due to PGE2 exposure 
were unsuccessful.  It is difficult to say whether reagent breakdown or compensation of the colors 
led to the differences.  The initial experiment, however, was performed using sorted cells and 
subsequent experiments used gradient-enriched cells with surface staining after exposure to 
bacteria and DHR.  Other than incidental mouse-to-mouse variation, it seems likely that the 
differences in the particular parameters of the initial experiment vs subsequent experiments led to 
the lack of positive results from the latter.   
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 We previously showed that gp91phox-/- PMN had no defect in killing Lm despite 
complete lack of ROS burst ((243), chapter 4).  Furthermore, the data in chapter 4 suggested that 
ROS in wild type mice, a reduction in ROS could result in a small but significant reduction in 
killing efficiency.  To understand if the effect of PGE2 on ROS extended beyond the initial 10-
minute time point and affected killing efficiency, gp91phox-/- PMN were incubated in 1 μM PGE2 
for 90 min before addition of Lm.  As shown in Fig. 5.4D, PGE2 pretreatment resulted in an 
approximate 15% decrease in wild type PMN killing efficiency but had no effect on the ROS-
deficient PMN, indicating that it indeed was affecting ROS in the wild type cells.  Together, these 
data suggest that PGE2 has numerous small effects on the multiple methods that PMN use to kill 
Lm. 
 
5.5 Discussion 
 PMN are recruited to Lm-infected liver and thought to be necessary for hepatic clearance 
of Lm, yet the connection of PMN killing efficiency to susceptibility in listeriosis has not been 
previously explored.  Our lab previously showed that bone marrow PMN from susceptible 
BALB/c and resistant B6 mice killed Lm with similar efficiency, indicating that upon egress from 
the marrow, these cells were likely to be in a similar state of readiness and suggesting that in the 
liver, they encounter an environment that changes their functional capacities.  In this study, we 
examine the effects of PGE2, an immunomodulatory lipid, and show that it is both produced at 
higher levels in the livers of susceptible animals and that PMN are less able to kill Lm in its 
presence.   
 It was not surprising to find PGE2 produced by fractionated BALB liver immune cells; 
however, it was unexpected to find that infection appeared not to induce PGE2 secretion in 
samples from B6 mice.  Whether this was due to a differential cell infiltrate at 3 dpi is unknown.  
Previous studies using macrophages have indicated that BALB cells possess more PGE2 binding 
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sites and produce more PGE2 after stimulation than B6 or C3H/HeN macrophages (149, 150), but 
to the best of our knowledge this is the first study to find differential secretion in the context of 
infection.   Unfortunately, we were unable to verify induction of COX-2 in response to in vivo 
infection.  However, two explanations exist for this.  First, a low percentage of total cells are 
likely to be infected at any given time in the liver after foodborne transmission.  It seems likely 
that COX-2 induction and/or PGE2 secretion are dependent on the presence of bacteria in 
neighboring cells, if not within the producing cell itself.  Furthermore, the extensive processing 
required to fractionate immune cells from the liver could easily negatively impact this staining. 
 The impact of PGE2 pretreatment on the ability of PMN to kill Lm was, on average, a 20-
30% loss of killing efficiency.  This means that in comparison with vehicle-treated cells, 
approximately 25% more bacteria escaped killing, remaining alive and able to replicate after 50 
min of contact with PMN. Since PMN are likely to accumulate in the liver over the course of 
several days after foodborne infection and be exposed to tonic as well as acute PGE2 secretion, 
these results are suggestive that the in vitro phenotype could also be observed in vivo.  Levy et al. 
proposed the idea of an “eicosanoid switch,” a process by which PMN are exposed to PGE2 for 
several hours and then begin to modulate their own dispersal by producing pro-resolution lipoxin 
A4 (160).  These results were supported by the recent work of Reategui et al. in which swarming 
PMN produced lipoxin A4 during the plateau phase of the swarm, thus changing their behavior 
pattern (109). 
 Many of these results are supportive of results others have obtained using other cell types 
and other forms of stimulation after PGE2 treatment.  The small but significant effects on 
chemotaxis, bacterial internalization, and ROS are also supportive of the larger phenotype, a 
defect in overall killing capacity in PMN.  Together, these results point to an immunomodulatory 
role for PGE2 during the context of bacterial infection that could easily play a part in other 
opportunistic infections.  Further work with the foodborne infection model and refinement of 
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techniques to measure PGE2 in the infected host will be required to elucidate the effects of PGE2 
on clearance of Lm.   
 
 
 
 
 
 
 
 
 
Figure 5.1  In vitro infection induces COX-2 upregulation 
Bone marrow-derived monocytes (GR1+CD64-), transitioning cells (GR1+CD64+), and 
macrophages (CD64+GR1-) were infected for 2 hr with Lm SD2000 (MOI=1) for 2 hr 
followed by addition of 25μg/ mL gentamicin.  COX-2 expression was assessed after 
overnight incubation. (A) A representative plot depicts the three cell types in culture at day 
four.  On the right, a representative COX-2 histogram for transitioning cells is shown with 
uninfected cells on the left and infected cells on the right.   (B) Percent COX-2+ cells for 
each cell type and COX-2 mean fluorescence intensity (MFI) and are shown.  Pooled results 
from three independent experiments are shown; bars indicate mean +/- SD. 
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Figure 5.2  In vivo Lm infection stimulates PGE2 secretion from liver non-parenchymal cells 
BALB and B6 female mice were fed 5 x 108 CFU Lm SD2000 and livers were harvested 3 dpi 
following collagenase perfusion. (A) Left- Monocyte infiltrate in the livers of uninfected (-) or 
infected (+) mice.  Each symbol represents one mouse; three pooled experiments are shown. 
Right- an example of a typical FACS profile of liver non-parenchymal cells is shown. Live, 
singlet, and CD45+ gates were incorporated prior to applying Ly6G and Ly6C gating. (B) Liver 
non-parenchymal cells were harvested from infected mice and stained for markers of B and T 
lymphocytes, PMN, monocytes, and Kupffer cells (KC).  COX-2 median fluorescence intensity is 
shown as change compared to uninfected cells. Each symbol represents one mouse; three pooled 
experiments are shown.  (C) Prostaglandin E Metabolite (PGEM) was measured from supernatant 
of clarified BALB liver homogenates.  Pooled results from two experiments are shown.  (D, E) 
Livers were harvested from infected mice after perfusion and collagenase digestion.  CFU burden 
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was determined from a portion of cells prior to depletion of hepatocytes (D) and the remainder 
was cultured overnight at 37°C in 7% CO2 for determination of secreted PGE2 (E).  Pooled 
results from three independent experiments; n=1-2 mice per repeat are shown.  (F) Non-
parenchymal cells from uninfected or infected BALB livers were stimulated by exposure to heat-
killed, sonicated Lm or infected in vitro.  (G) BALB females were treated with indomethacin 
every 12h beginning 24 hpi.  Organs and blood were harvested at 72 hpi.  (H) Female B6 mice 
were treated with 16,16 dmPGE2 once daily beginning immediately after infection and organs 
were harvested at 4 dpi.  Results from one experiment are shown, bars indicate mean +/- SD. 
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Figure 5.3  PGE2 pretreatment results in a dose-dependent loss of killing efficiency in 
murine PMN 
(A) BALB/c and B6 PMN were incubated with the indicated concentrations of PGE2 for 30 or 90 
min. before 50 min incubation with Lm (MOI=1).  Representative results; n=4 replicates per 
treatment, are shown.  Bars indicate mean +/- SD.  Below this, the number of CFU per well are 
shown for one representative experiment in which Lm (MOI=1 or 10) were either incubated for 
50 min alone to measure growth, with PMN that had received vehicle treatment, or with PMN 
that were pretreated with 1μM PGE2.  Dotted line indicates initial inoculum.  Representative 
results are shown for one of two independent experiments; n=5 technical replicates per treatment, 
bars indicate mean +/- SD. (B) Pooled results are shown for experiments where PMN were 
incubated with 1 μM PGE2 for 60-90 min.  Each symbol represents the mean for one experiment. 
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(C) (Top) BALB and B6 PMN were incubated with 1 uM PGE2 concurrently with 100 nM EP-2 
antagonist PF-04418948 or EP4-antagonist L-161,982 prior to addition of Lm (MOI=1). 
Representative results for a killing assay are shown; n=3 technical replicates per treatment.  Bars 
indicate mean +/- SD. (Bottom) Pooled, normalized results for three independent experiments 
with three technical replicates per treatment are shown.  Each symbol represents the mean of one 
experiment. 
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Figure 5.4  PGE2 exerts pleiotropic effects on PMN function 
(A) Gradient enriched PMN were suspended in media containing 1 uM PGE2, incubated for 5 
min, and applied to an under-agarose assay with 1000 nM LTB4 as the attractant in a well that 
was 1mM away from the wells containing cells. Results from one experiment are shown; n= 4 
technical replicates per treatment.  (B) FACS-sorted BALB/c PMN were incubated in 1 μM 
PGE2 for 90 min prior to addition of Lm SD2710.  Percent of cell-associated bacteria at 10 mpi 
found intracellularly using in/out staining is shown. Results from one experiment are shown; n=3 
technical replicates per treatment.   (C) FACS-sorted PMN were incubated in 1 μM PGE2 for 90 
min prior to addition of DHR and M-cherry expressing Lm.  Percent of PMN positive for M-
cherry at 10 and 30 mpi is shown on the left, and percent of ROS+ cells is shown on the right.  
Representative results for one of two experiments are shown (D) Bone marrow PMN from B6 
and gp91phox-/- mice were sorted, exposed to 1 μM PGE2 for 90 min, and then incubated with 
Lm.  Percent of inoculum killed at 50 mpi is shown; n=5 technical replicates per treatment, 
representative results from one of two experiments.  In all cases, bars indicate mean +/- SD. 
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6.  Discussion, conclusions, and future directions 
 Listeriosis in humans is lethal in approximately 25% of all diagnosed cases (12, 13), yet 
surprisingly little is known about its natural course of infection.  Some of this is due to listeriosis 
being a relatively “new” recognized disease.  In fact, although the bacterium was described in 
1926 (244) and there were periodic outbreaks of illness attributed to foodstuffs, research on Lm as 
a serious human pathogen did not begin until the mid-1980s.     For years, however, Lm was used 
as a tool for immunology discovery rather than studied as an important foodborne pathogen.  Lm 
has been considered a model intracellular pathogen for years, and intravenous infection of mice 
with Lm has yielded results that are now pillars of immunology and pathogenesis knowledge.  
Much of what we now know regarding how intracellular bacteria invade cells and escape 
phagosomal killing, as well as the necessity of IFNγ for clearance of intracellular bacteria can be 
attributed to use of Lm. 
 Intravenous infection has also been a method used to skirt the problem that mice are not a 
natural host for Lm.  Doses in excess of 1010 Lm could be given to wild type mice via gavage with 
no impact on survival (29), while significantly lower doses of ~103-104 bacteria were required to 
observe liver and spleen invasion and even rapid death using intravenous inoculation (46, 212)  
This was because of a single amino acid mismatch between a key virulence determinant needed 
for entry of non-phagocytic cells, InlA, and E-cadherin, its receptor on enterocytes (30).  To 
improve the efficiency of murine infection by the oral route, Lecuit et al. created a “humanized” 
mouse expressing enterocyte-restricted human E-cadherin (29) and later Wollert et al. created a 
“murinized” version of InlA, termed “InlAm” (58).  These groups and many others, however, still 
used gavage, a sometimes-traumatic method by which bacteria are delivered directly to the 
stomach, for infections.  When Bou Ghanem et al. later developed a method of foodborne 
transmission of Lm in mice, InlA was not found to be required to establish intestinal infection, but 
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InlAm enhanced persistence in the underlying intestinal tissue and spread to the mesenteric lymph 
nodes (35). 
 Still, however, little of the pathway from the stomach to the intestinal lamina propria to 
the extra-intestinal organs has been explained.  Melton-Witt et al. orally infected guinea pigs with 
tagged Lm clones and used mathematical modeling to conclude that only approximately 1 in 106 
Lm will invade the intestinal epithelium (72).  Becattini et al. recently showed that in mice with a 
healthy microbiota, Lm was significantly less able to invade and disseminate to other organs than 
in mice which had received antibiotic treatment, indicating an important role for intestinal 
microbiota and their products in protection against pathogenic bacteria (181).  These data indicate 
that very low numbers of Lm will be able to successfully pass through the cadre of immune cells 
waiting in the lamina propria and subsequently be transported to the liver and spleen.  Despite 
encountering multiple barriers to invasion and dissemination bottlenecks, Lm causes very serious 
disease when it overcomes initial barriers.  Thus, it is important to understand how dissemination 
occurs and the host immune responses that occur at each step of the pathway.   
 The area that I chose to focus on for my dissertation work was host immune responses, 
first in the spleen and then in the liver.  Much is known about how intravenously inoculated Lm 
are taken up by the liver and spleen (64, 76, 78), but relatively little has been determined 
regarding the immune responses that are triggered when (presumably) small numbers of stress-
adapted bacteria arrive to these organs after foodborne infection.  Apart from the clear necessity 
for IFNγ for Lm clearance, even less is known about what local and systemic mediators are 
induced by dissemination of foodborne bacteria and how these mediators influence the course of 
infection.  Some of these mediators can have opposing effects depending on their timing, tissue, 
and stimulus, which could be important as a pathogen like Lm moves slowly out of the intestine 
and into the peripheral organs.  Therefore, chose to examine type I IFN and PGE2, two mediators 
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more classically-known as pro-inflammatory but which had previously been shown to have anti-
inflammatory roles in certain tissues and environments. 
   Initially, I focused on the “type I IFN response” to Lm in the spleen, a phenotype that 
was first observed when IFNAR1-/- mice were found to be more resistant to intravenous Lm 
infection than their wild type counterparts (142, 143, 145).  Later however, another group 
concluded that type I IFN signaling was necessary for defense against Lm infection after 
intragastric inoculation of Lm LO28, a strain that causes hyper-induction of IFNβ secretion (126, 
189).    Much of the resistance phenotype found after i.v. infection was attributed to IFNα/β-
dependent downregulation of IFNγR1, which was thought to decrease macrophage activation 
(83).  The results presented in chapter three, however, suggest that type I IFN is inconsequential 
in the course of foodborne listeriosis. This work showed that IFNAR1-/- mice were not resistant to 
foodborne Lm infection in comparison to wild type B6 controls and that little, if any, type I IFN 
was produced in the spleen after foodborne infection.  Importantly, this work also showed that 
downregulation of the IFNγ receptor was a consequence of infection, rather than a consequence 
of type I IFN signaling.  It seems likely that during the course of infection, IFNγ is naturally 
secreted and the receptor is simply internalized after binding its ligand.  It is undisputed that type 
I IFN can cause downregulation of IFNGR1; however, this appears to only be of importance in 
high dose experimental i.v. infection thus far. 
 Overall, the results shown in chapter three indicate that while type I IFN can play an 
important role in the pathogenesis of Lm infection, its induction is strongly dependent on the 
route of infection.  If work in the Listeria field were to move forward with type I IFN, it seems 
reasonable to ask if type I IFN is routinely found in samples from positively diagnosed patients.  
IFNα/β secretion is a part of innate immunity, however, meaning that it is produced early in the 
course of infection, therefore finding it in patients days to weeks after consumption of 
contaminated foods could prove difficult.  The most relevant scenario might actually be maternal-
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fetal transmission, which occurs via the bloodstream or invasion of the placenta.  Interestingly, 
Cappelletti et al. recently found that stimulation of type I IFN signaling in pregnant mice induced 
preterm birth (245), suggesting that a pathogen that invades the placenta and causes robust 
IFNα/β signaling could be the cause of some miscarriages and spontaneous abortions.   
 PGE2 is a lipid mediator well-known for its roles in pain and fever; however emerging 
evidence has pointed to PGE2 as an anti-inflammatory compound in certain settings (152, 153, 
162).  I hypothesized that PGE2 played an anti-inflammatory role in the liver after foodborne 
infection by blunting the effector functions of PMN, which are recruited to the liver after 
infection and necessary for Lm clearance (53, 91, 93, 94).  In turn, this lack of bacterial killing in 
the early phase of Lm colonization of the liver contributed significantly to the susceptibility 
observed in BALB mice, particularly in the liver.  In order to understand how PGE2 affected 
PMN in the context of infection, it was necessary to first understand how PMN interacted with 
and killed Lm. This provided an opportunity to study PMN from both Listeria-susceptible BALB 
mice and resistant B6 mice and to determine if any key differences existed between PMN from 
these two strains.  Most differences in susceptibility to intracellular bacteria between these two 
strains have been attributed to facets of innate immunity including differential secretion of IFNγ 
(48-50), yet the ability of PMN to directly kill Lm had not been examined.   I hypothesized that 
PMN from both mice would kill Lm similarly, but that BALB PMN encountered a suppressive 
microenvironment in the liver, thus blunting their normally highly bactericidal effector functions.  
Mouse PMN are not routinely used in studies of bacteria-PMN interactions, both because PMN 
are easily obtained from human blood samples as well as because of perceived differences 
between murine and human PMN.  The results shown in chapter 4 suggest that for pathogens 
which elicit a strong PMN response such as Francisella tularensis and Streptococcus pyogenes, 
studies using mouse bone marrow PMN would provide useful information on how these 
pathogens are killed by or evade PMN killing.  In particular, Francisella tularensis, another 
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intracellular pathogen, elicits a robust PMN response to the lungs but is also one of the few 
pathogens known to parasitize PMN (for a review, see Allen, L.A. 2016, Frontiers in Cellular 
and Infection Microbiology).  The Francisella field has also undergone some of the same 
evolution of knowledge regarding the necessity for PMN in early clearance as Listeria has.  With 
the knowledge that mouse bone marrow PMN are relatively long-lived an amenable to sorting 
and other manipulations, it would be worthwhile to understand how the functional “age” (i.e. 
relatively young bone marrow PMN vs “older” circulating PMN) and activation markers affect 
this unusual phenotype. 
 With regard to continuing this research line with Listeria, the possibilities are almost 
endless.  Understanding how the tissue microenvironment affects PMN expression of homing 
markers CXCR1, CXCR2, receptors for leukotriene B4, and the formyl peptide receptors should 
be of foremost importance, as PMN are needed for clearance but also contribute to tissue damage 
in listeriosis.  The under-agarose assay is a crude measure of chemotaxis, and other, more 
sophisticated methods should be considered including simple microfluidic assays.  Although it 
provided a useful measure of movement, the under-agarose assay lacks the ability to control for 
the weight of the agarose or small variations in the thickness and purity of the agarose that could 
impede movement.  I was also unable to verify Listeria-specific chemotaxis, as the 
chemoattractant used in these assays must be able to rapidly diffuse into the agarose to create a 
concentration gradient.  Use of purified liver PMN rather than bone marrow PMN to assess 
chemotaxis would also improve the physiological relevance of this data; however, this will 
require a method to cleanly extract PMN from the liver, however, without inadvertently providing 
activation or apoptosis signals. 
 Although it provided the data necessary to answer the question at hand, Figure 4.4 also 
raises some interesting questions also that should be answered in the future.  In Figure 4.4C, a 
very small percentage of inoculated bacteria are intracellular at 25 mpi.  This in itself is not 
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impressive, as PMN are likely to initiate killing mechanisms nearly as soon as the phagocytic 
vacuole closes, thus most of the bacteria phagocytosed early were already degraded.  The time 
points after this, though, show that the number of intracellular bacteria remains low but steady, 
suggesting some level of survival inside PMN.  Importantly, however, the cells used in these two 
assays were gradient-enriched, meaning that a significant percentage of the cells were not PMN 
and could potentially allow Lm to exist or grow.  A follow-up experiment to this should include 
sorted PMN and time points of 15 min-2 hr after inoculation. 
 The role of PGE2 in Lm pathogenesis is potentially far more complex than that of type I 
IFN and is something that should be further explored.  Even as it plays important roles in 
regulation of blood pressure, kidney function, and induction of IL-6 (173, 174, 246), PGE2 could 
be playing a pathogenic role in the progression of listeriosis. Most study of the effects of PGE2 
has dealt with isolated capabilities of phagocytes, such as showing decreased phagocytosis, or a 
reduction in TNFα secretion (153, 177).  Here, I attempted to look at the whole picture and 
hypothesized that PGE2 was secreted at high levels in the BALB liver after infection and was 
thereby able to decrease the killing efficiency of PMN recruited to this site of infection.  A 
cartoon depicting the overall hypothesis for this research is depicted in Fig. 6.1.  PMN are 
primary effector cells in a variety of situations, including listeriosis, tularemia, candidiasis, and 
even cuts and scrapes.  If PMN exit the bone marrow able to effectively neutralize virulent 
bacteria, and then encounter a microenvironment that downregulates that ability to kill before 
they have done their job, it is almost certain that this decreased capability will be apparent in 
higher disease burdens.  Likewise, PMN have to be controlled so as to prevent inadvertent tissue 
damage as a result of their many methods of neutralizing bacteria.  This could be of special 
importance in cases of immune compromise, where eicosanoid secretion is likely to be 
dysregulated already.   
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 I found that PGE2 was both produced at higher levels by liver cells from susceptible 
BALB animals than from B6 animals and that PGE2 effectively down-modulated the killing 
efficiency of unprimed bone marrow PMN.  These results are supportive of numerous other 
reports showing inhibition of cell functions such as phagocytosis in macrophages and decreased 
production of ROS in PMN (153, 177), but to the best of my knowledge, this is the first report of 
PGE2 exposure decreasing the ability of any cell to kill a pathogenic bacterium.  The especially 
intriguing part of these results, however, may be that PGE2 did not just have one effect on PMN.  
Instead, these data suggest that PGE2 may modulate PMN motility, internalization of bacteria, 
and production of reactive oxygen species.  These may all represent a target for therapeutic 
intervention in the liver and beyond as we look for ways to augment human immunity to disease 
without the use of antibiotics.  
 This research could be taken in several different directions.  The connection of PGE2 
secretion to aging and susceptibility to listeriosis should be more fully explored in particular.  
Experiments could include PMN behavior tracking using bone marrow from aged mice, 
foodborne infection of aged mice, and blood samples from elderly human donors.  Given the 
known roles for PGE2 in aging and inflammation, I would hypothesize that PMN from elderly 
samples are sensitive to the effects of PGE2 and are less able to migrate toward and kill bacteria 
than PMN from young samples.   
 The best way to elucidate the effects of PGE2 on PMN function in the context of the liver 
might actually be an adoptive transfer.  PMN could be antibody depleted from BALB/c mice and 
PMN from congenic mice adoptively transferred in at the time of infection.  The time course of 
foodborne infection along with PMN recruitment to the liver might present some challenges, but 
performing this experiment using i.v infection would yield some context as to whether further 
efforts should be undertaken to do the depletion for foodborne infection or not.  
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 The idea presented by Levy et al. of an “eicosanoid switch” (160) should also be 
explored.  Are PMN in the liver, in the presence of high levels of PGE2, induced to secrete 
lipoxin A4, thus resulting in resolution of PMN swarming?  Does “resolution” happen before it 
should, or do B6 mice resolve PMN-mediated inflammation early on, thus alleviating the 
prospect of tissue damage?  A first step in these experiments would be to sort PMN and treat with 
PGE2 for 6-8 hours before assessing killing ability.  I would hypothesize that a very long 
exposure to PGE2, possibly with “boosters” would result in severe down regulation of PMN 
chemotaxis and killing, coinciding with increased transcription of 15-lipoxygenase.  Following 
this set of experiments, lipoxin A4 could be measured by EIA and also added exogenously. 
 Much of the immune response to foodborne bacteria remains underexplored.  Overall, the 
results presented in these chapters suggest that immune mediators during foodborne infection can 
have very different roles given unique stimuli, tissue environments, and timing.  More so than any 
other infection route, infections acquired from consumption of contaminated foods are likely to 
cause unique immune responses in multiple areas of the host as they disseminate and colonize 
their preferred tissues.  Future study of foodborne infections should take into account the unique 
role of local and systemic mediators not traditionally considered to be a major factor in bacterial 
pathogenesis.    
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Figure 6.1 Hypothesis: Overproduction of PGE2 in the BALB liver decreases PMN killing 
efficiency 
BALB and B6 mice both consume Lm, which invades the intestine and disseminates to the liver 
in similar numbers in both mice.  The bacterial insult triggers recruitment of PMN to the livers of 
both mice that emerge from the bone marrow similarly able to kill bacteria In the BALB mouse, 
however, the arrival of the bacteria triggers overproduction of PGE2 that is not observed in the 
B6 mouse. This PGE2 then causes a reduction in multiple parameters of PMN function, leading 
to a decrease in overall PMN killing efficiency in the BALB liver. 
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Appendix I: List of abbreviations 
AMP/ c-di-AMP= adenosine monophosphate/ cyclic-di-adenosine monophosphate 
BALB/ BA= BALBcBy/J mouse, a strain of mouse that is susceptible to Listeria infection 
B6= C57BL/6J mouse, a strain of mouse that is relatively resistant to Listeria infection 
BHI= brain heart infusion (broth or agar) 
CD (e.g. CD4, CD86)= cluster of differentiation 
CFU= colony forming units 
COX-2= cyclooxygenase enzyme 2 
DHR= dihydrorhodamine 123 
DNA= deoxyribonucleic acid 
dpi= days post infection 
EIA= enzyme immunoassay 
ELISA= enzyme-linked immunosorbent assay 
FACS= fluorescence activated cell sorting 
hpi= hours post infection 
IFN= interferon 
IFNAR= interferon alpha/beta receptor 
IFNγR= interferon gamma receptor  
i.g.= intragastric 
Inl (A/B)= internalin 
KC= Kupffer cell 
IL= interleukin 
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i.p.= intraperitoneal 
i.v.= intravenous 
JAK= Janus kinase 
Lm = Listeria monocytogenes 
LO/ LOX= lipoxygenase 
LSEC= liver sinusoidal endothelial cell 
LTB4= leukotriene B4 
M= molar (micro, nano) 
mΦ= macrophage 
MAPK= mitogen-activated protein kinase 
MFI= mean fluorescence intensity 
MHC= major histocompatibility complex 
mPGES= microsomal prostaglandin E synthase 
mpi= minutes post infection 
NI= not infected 
NK cell= natural killer cell 
NSAID= non-steroidal anti-inflammatory drug 
PG/ PGE2= prostaglandin/ prostaglandin E2 
PLA2= phospholipase A2 
PMN= neutrophil polymorphonuclear leukocyte 
PrfA= positive regulatory factor A 
RNA= ribonucleic acid 
109 
 
ROS= reactive oxygen species 
SD= standard deviation 
STAT= signal transducer and activator of transcription 
STING= stimulator of interferon-related genes 
TLR= toll-like receptor 
TRAIL= tumor necrosis factor alpha apoptosis-inducing ligand 
TNFα= tumor necrosis factor alpha  
TYK= tyrosine kinase 
UTR= untranslated region 
VCAM= vascular cell adhesion molecule 
VLA4= very late antigen 4 
WT= wild-type  
α= alpha 
β= beta 
∆= delta, deletion 
γ= gamma 
κ= kappa 
μ= micro 
σ= sigma 
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